A compound with antispore activity and its pharmaceutical composition

By developing new cholic acid compounds and using specific substituents and amino acid ester group structures, the problems of high recurrence rate of treatment of infectious diseases of C. difficile and limited inhibitory activity of cholic acid compounds in the prior art have been solved, and the difficulties have been achieved Effective inhibition and disease prevention effects of Clostridium spores.

CN113135970BActive Publication Date: 2024-11-22CHENGDU BIOBEL BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202010066592.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-01-20
Publication Date
2024-11-22
Estimated Expiration
2040-01-20

AI Technical Summary

Technical Problem

After the existing antibiotics treat C. difficile infectious diseases, the recurrence rate of patients is high, and the existing bile acid compounds have limited inhibitory activity on C. difficile spores, making it difficult to effectively prevent and treat C. difficile infection.

Method used

A novel cholic acid compound has been developed, with a structure including specific substituents and amino acid ester groups, and a highly active antibacterial agent is prepared through a specific chemical synthesis route to effectively inhibit the germination of C. difficile spores.

Benefits of technology

This new cholic acid compound significantly inhibits the germination of C. difficile spores, has a high effect in preventing and treating C. difficile infectious diseases, and reduces the risk of disease recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113135970B_ABST
    Figure CN113135970B_ABST
Patent Text Reader

Abstract

The present invention provides a compound having antispore activity and a pharmaceutical composition thereof, specifically providing a compound represented by formula (I), or a salt thereof, or a stereoisomer thereof. The compound can effectively inhibit the germination of Clostridium difficile spores, has significant antibacterial activity, and has a very good application prospect in the preparation of drugs for preventing and / or treating Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases, or complications of Clostridium difficile infectious diseases. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to a cholestane derivative with antibacterial spore activity and a pharmaceutical composition thereof. Background Art

[0002] Clostridium difficile is an obligate anaerobic bacterium of the genus Clostridium. It is very sensitive to oxygen and difficult to isolate and culture, hence its name. It generally parasitizes in the human intestine. Clostridium difficile infection is usually caused by excessive use of certain antibiotics, which disrupts the balance of intestinal flora, accelerates the growth rate of Clostridium difficile flora, and causes inflammation. Clostridium difficile produces exotoxins A and B, which have different effects at different times. Toxin A is an enterotoxin that first binds to mucosal cells in the early stages, causing primary damage, which can cause inflammation of the intestinal wall, cell infiltration, increased intestinal wall permeability, bleeding and necrosis. Toxin B is a cytotoxin that damages the cytoskeleton, causes cell shrinkage and necrosis, and directly damages intestinal wall cells, leading to diarrhea.

[0003] Clostridium difficile infectious disease is a disease caused by infection with Clostridium difficile bacteria and / or Clostridium difficile spores. Pseudomembranous colitis is a common Clostridium difficile infectious disease, with clinical manifestations of diarrhea, abdominal pain, and systemic poisoning symptoms. The symptoms begin suddenly, accompanied by low blood pressure, usually accompanied by fever, leukocytosis, and can later lead to death. It is a very serious type of disease. In addition, infection with Clostridium difficile bacteria and / or Clostridium difficile spores may also cause complications of Clostridium difficile infectious diseases. Common complications include pyelonephritis, meningitis, abdominal and vaginal infections, bacteremia, and gas gangrene. In recent years, Clostridium difficile has become an important pathogen causing nosocomial infectious diseases and has been increasingly valued by people.

[0004] The main treatment for Clostridium difficile infection is currently the use of antibacterial agents. Metronidazole and vancomycin are the two most commonly used antibacterial agents. However, patients with Clostridium difficile infection who have been treated with metronidazole and vancomycin have a higher chance of recurrence. Considering that blocking spore infection is an effective way to prevent and treat Clostridium difficile infection, it is urgent to develop new antibacterial agents with high activity that inhibit Clostridium difficile spores.

[0005] Bile acid compounds are a class of structurally similar tetracyclic fused steroid compounds containing 23-25 ​​carbon atoms, belonging to the class of steroid acid compounds. Bile acid compounds are commonly used to treat hepatobiliary diseases; the public literature The Journal of Infectious Diseases 2013; 207: 1498-504 and J. Med. Chem. 2018, 61, 6759-6778 reported that bile acid derivatives have the activity of inhibiting the germination of Clostridium difficile spores, but the activity of their compounds in inhibiting spores is limited.

[0006] Therefore, it is of great significance to develop new antibacterial agents with high activity that inhibit Clostridium difficile spores. Summary of the invention

[0007] The purpose of the present invention is to provide a novel bile acid compound having high activity and capable of inhibiting the germination of Clostridium difficile spores and a pharmaceutical composition thereof.

[0008] The present invention provides a compound represented by the following formula (I), or a salt thereof, or a stereoisomer thereof:

[0009]

[0010] Wherein, R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from H, -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; wherein m = an integer from 0 to 9; wherein an amino acid ester group is the group remaining after removing a hydrogen atom from the carboxyl group on the amino acid;

[0011] Alternatively, R1 and R2, R5 and R6, and / or R7 and R8 are connected to form a double bond;

[0012] R9 is selected from H, or R9 is connected to R4 or R5 to form a double bond;

[0013] R 10 Selected from H, C 1-13 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0014] A and B are independently selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, and cycloalkyl;

[0015] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0016] It is a single bond or a double bond.

[0017] Furthermore, the compound of formula (I) has a structure as shown in the following formula (IIA):

[0018]

[0019] Wherein, R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from H, -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; wherein m = an integer from 0 to 9;

[0020] Alternatively, R1 and R2, R5 and R6, and / or R7 and R8 are connected to form a double bond;

[0021] R9 is selected from H, or R9 is connected to R4 or R5 to form a double bond;

[0022] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0023] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl;

[0024] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0025] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2)n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0026] Furthermore, the compound of formula (IIA) has a structure as shown in the following formula (IIIA-1) or (IIIA-2):

[0027]

[0028] Wherein, R5, R6, R8 are independently selected from H, -OH, -NH2, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3, wherein m=an integer from 0 to 9;

[0029] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0030] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0031] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0032] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0033] Furthermore, the compound of formula (IIIA-1) has the structure described by the following formula (IVA-1):

[0034]

[0035] Wherein, R6 is selected from -OH, -NH2, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3, the amino acid ester group is an α-amino acid ester group, wherein m=an integer from 0 to 9;

[0036] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0037] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0038] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0039] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0040] Furthermore, the compound of formula (IIIA-1) has a structure as described in the following formula (VA-1):

[0041]

[0042] Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) nCOOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0043] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0044] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0045] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N((CH2) n2 CH3)2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0046] Furthermore, the compound of formula (IIIA-1) has a structure as shown in the following formula (VIA-1):

[0047]

[0048] Wherein, R5 is selected from -OH, -NH2, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3, the amino acid ester group is an α-amino acid ester group, wherein m=an integer from 0 to 9;

[0049] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0050] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0051] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0052] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0053] Furthermore, the compound of formula (IIIA-1) has a structure as shown in the following formula (VIIA-1):

[0054]

[0055] Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0056] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0057] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0058] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N((CH2) n2 CH3)2, -COCH3, -CO(CH2) n3COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0059] Furthermore, the compound of formula (IIIA-1) has a structure as shown in the following formula (VIIIA-1):

[0060]

[0061] Wherein, R5 and R6 are selected from -OH, -NH2, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3, the amino acid ester group is an α-amino acid ester group, m=an integer of 0-9;

[0062] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0063] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0064] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0065] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0066] Furthermore, the compound of formula (IIIA-1) has a structure as shown in the following formula (IXA-1):

[0067]

[0068] Among them, R10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0069] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0070] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0071] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0072] Furthermore, the compound of formula (IIIA-1) has a structure as shown in the following formula (XA-1):

[0073]

[0074] Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0075] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0076] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0077] R 11 , R12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0078] Furthermore, the compound of formula (IVA-1) has a structure as described in formula (XIA-1) or (XIA-2):

[0079]

[0080] Among them, R 10 Selected from H, C 1-4 Alkyl, cyclopropyl;

[0081] R6 is selected from -OH, -NH2, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3, the amino acid ester group is an α-amino acid ester group, wherein m=an integer from 0 to 9;

[0082] R 11 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0083] Furthermore, the compound of formula (VA-1) has a structure as described in formula (XIIA-1) or (XIIA-2):

[0084]

[0085] Among them, R 10 Selected from H, C 1-4 Alkyl, cyclopropyl;

[0086] R 11 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0087] Furthermore, the compound of formula (IIA) has a structure as shown in the following formula (IIIB):

[0088]

[0089] Wherein, R5, R6, and R8 are independently selected from H, -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; wherein m = 0-9;

[0090] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0091] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0092] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0093] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0094] Furthermore, the compound of formula (IIA) has a structure as shown in the following formula (IIIC):

[0095]

[0096] Wherein, R5, R6, and R8 are independently selected from H, -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; wherein m = an integer from 0 to 9;

[0097] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0098] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0099] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0100] R 11 , R 12 , R 13 independently selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0101] Furthermore, the compound of formula (IIIB) has a structure as shown in the following formula (IVB-1), (IVB-2) or (IVB-3):

[0102]

[0103] Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0104] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0105] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0106] R 11 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0107] Furthermore, the compound of formula (IIIB) has a structure as shown in the following formula (VB-1):

[0108]

[0109] Wherein, R6 is selected from -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; the amino acid ester group is an α-amino acid ester group, wherein m=an integer of 0-9;

[0110] R 10 Selected from H, C1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0111] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0112] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0113] R 11 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0114] Furthermore, the compound of formula (IIIC) has a structure as shown in the following formula (IVC-1), (IVC-2) or (IVC-3):

[0115]

[0116]

[0117] Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0118] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0119] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0120] R 11Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, (CH2) n2 COOH, N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0121] Furthermore, the compound of formula (IIIC) has a structure as shown in the following formula (VC-1):

[0122]

[0123] Wherein, R6 is selected from -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; the amino acid ester group is an α-amino acid ester group, wherein m=an integer of 0-9;

[0124] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0125] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0126] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0127] R 11 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0128] Furthermore, the compound of formula (I) has a structure as shown in the following formula (IID):

[0129]

[0130] Wherein, R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from H, -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; wherein m = an integer from 0 to 9;

[0131] Alternatively, R1 and R2, R5 and R6, and / or R7 and R8 are connected to form a double bond;

[0132] R9 is selected from H, or R9 is connected to R4 or R5 to form a double bond;

[0133] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0134] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl;

[0135] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0136] R 14 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0137] Furthermore, the compound of formula (IID) has a structure as shown in the following formula (IIID):

[0138]

[0139] Wherein, R6 is selected from -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; the amino acid ester group is an α-amino acid ester group, wherein m=an integer of 0-9;

[0140] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0141] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0142] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0143] R 14 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0144] Furthermore, the compound of formula (IID) has a structure as shown in the following formula (IVD):

[0145]

[0146] Among them, R 10 Selected from H, C 1-4Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0147] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0148] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0149] R 14 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0150] Furthermore, the compound of formula (I) has a structure as shown in the following formula (IIE):

[0151]

[0152] Wherein, R1, R2, R3, R4, R5, R6, R7, R8 are independently selected from H, -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; wherein m = an integer from 0 to 9;

[0153] Alternatively, R1 and R2, R5 and R6, and / or R7 and R8 are connected to form a double bond;

[0154] R9 is selected from H, or R9 is connected to R4 or R5 to form a double bond;

[0155] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2)n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0156] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl;

[0157] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0158] R 15 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0159] Furthermore, the compound of formula (IIE) has a structure as shown in the following formula (IIIE):

[0160]

[0161] Wherein, R6 is selected from -OH, C 1-5 Alkoxy, -NH2, =O, =S, =NOH, -NHSO3H or its salt, -OSO3H or its salt, -OPO(OH)2 or its salt, -OCO(CH2) m COOH or its salt, amino acid ester group or its salt, -OCO(CH2) m CH3; the amino acid ester group is an α-amino acid ester group, wherein m=an integer of 0-9;

[0162] R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0163] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0164] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0165] R 15 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0166] Furthermore, the compound of formula (IIE) has a structure shown in the following formula (IVE):

[0167]

[0168] Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH2) n COOH, -(CH2) n+1 NH2, -(CH2) n -B; wherein n = an integer from 0 to 4;

[0169] B is selected from substituted or unsubstituted benzene ring, thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyridine, pyrimidine, pyrazine, benzothiophene, indole, benzothiazole, cycloalkyl; the substituent on B is selected from halogen, methyl, methoxy;

[0170] Wherein cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;

[0171] R 15 Selected from H, -OH, -NH2, C 1-3 Straight or branched alkyl, C 3-6 N heterocycle, -NO2, -CHO, sulfonic acid, F, Cl, Br, I, -O(CH2) n2 CH3, -(CH2) n2 COOH, -N[(CH2) n2 CH3]2, -COCH3, -CO(CH2) n3 COOH; wherein n2=an integer from 0 to 3, and n3=an integer from 1 to 6.

[0172] Furthermore, the compound is selected from the following compounds:

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188] The present invention discloses the use of the above compound, or its salt, or its stereoisomer in preparing an antibacterial agent.

[0189] Furthermore, the antibacterial agent is a drug that inhibits the germination of Clostridium difficile spores.

[0190] Furthermore, the drug can prevent and / or treat Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases or complications of Clostridium difficile infectious diseases.

[0191] Further, the Clostridium difficile infectious disease, recurrence of Clostridium difficile infectious disease, or complication of Clostridium difficile infectious disease is caused by infection with Clostridium difficile spores;

[0192] The Clostridium difficile infectious disease complication is a digestive tract infection syndrome caused by Clostridium difficile spore infection.

[0193] Furthermore, the digestive tract infection syndrome is selected from pseudomembranous enterocolitis, diverticulitis, and antibiotic-associated diarrhea.

[0194] The present invention also provides a drug for inhibiting Clostridium difficile spores, wherein the drug is a preparation prepared by using any of the above compounds, or salts thereof, or stereoisomers thereof as active ingredients and adding pharmaceutically acceptable excipients.

[0195] Furthermore, the pharmaceutically acceptable excipient is selected from any one or more of a diluent, a filler, a colorant, a glidant, a lubricant, a binder, a stabilizer, a suspending agent or a buffer.

[0196] Furthermore, the preparation is an oral preparation;

[0197] Preferably, the oral preparation is selected from granules, capsules, tablets, and pills.

[0198] Furthermore, the dosage of the active ingredient contained in the pharmaceutical unit preparation is 5-2500 mg.

[0199] The unit preparation described in the present invention refers to one preparation unit, such as one tablet, one capsule, one bag of granules, one bag of pills, or one capsule filled with pills.

[0200] The "α-amino acid ester group" of the present invention refers to the group remaining after removing a hydrogen atom from the carboxyl group on the α-amino acid, such as -OCOCH2NH2.

[0201] Experiments have shown that the compounds provided by the present invention can effectively inhibit the germination of Clostridium difficile spores, have significant inhibitory activity, and have very good application prospects in the preparation of drugs for preventing and / or treating infectious diseases caused by Clostridium difficile spores, recurrence of Clostridium difficile infectious diseases, or complications of Clostridium difficile infectious diseases.

[0202] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0203] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. DETAILED DESCRIPTION

[0204] Unless otherwise specified, the raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.

[0205] 1. Synthesis of decarbonized bile acid intermediates:

[0206] The decarbonated (nor) bile acids used in the present invention include nor-CA (decarbonated cholic acid), nor-CDCA (decarbonated chenodeoxycholic acid), nor-UDCA (decarbonated ursodeoxycholic acid), nor-HCA (decarbonated hyodeoxycholic acid), nor-LCA (decarbonated lithocholic acid), and nor-HDCA (decarbonated hyodeoxycholic acid). The synthesis methods are all carried out according to the method of Journal of Lipid Research, 1988, 29:1387.

[0207]

[0208]

[0209] Taking nor-UDCA (negative ursodeoxycholic acid) as an example, the synthesis method is as follows:

[0210] Step 1: 20 g of UDCA was mixed with formic acid solution and catalytic amount of perchloric acid, stirred overnight, and concentrated under reduced pressure. The residue was treated with a toluene / petroleum ether (1:1) mixture to obtain a white solid.

[0211] Step 2: The above white solid was mixed and dissolved with 100 ml of trifluoroacetic acid / trifluoroacetic anhydride without purification, 5 equivalents of sodium nitrite were gradually added in batches at room temperature, and slowly heated to 40-50 degrees with stirring. After 30 minutes, it was cooled to room temperature, and ice water / toluene was added to quench the reaction. The aqueous layer was extracted with toluene, the toluene layers were combined, and the oil was obtained after concentration under reduced pressure.

[0212] Step 3: Add 100 ml of ethanol / 20% sodium hydroxide mixed solution to the above oily substance and heat under reflux until the reaction is complete, and cool and crystallize to obtain a carbonyl cyanide intermediate.

[0213] Step 4: The intermediate is stirred and refluxed with an isopropanol / sodium hydroxide system for 24 hours until the cyano group is hydrolyzed to a carboxyl group, and the solvent is concentrated under reduced pressure, and then the acid is adjusted to precipitate a white solid. Further purification is performed by recrystallization or column chromatography to obtain nor-UDCA (ursodeoxycholic acid) with a HPLC purity of >95% and a yield of 55-68%.

[0214] Similarly, using the corresponding CA (cholic acid), CDCA (chenodeoxycholic acid), HCA (hyodeoxycholic acid), LCA (lithocholic acid), and HDCA (hyodeoxycholic acid) as raw materials, the above steps were followed to prepare nor-CA (anorthocarbonic acid), nor-CDCA (anorthocarbonic chenodeoxycholic acid), nor-HCA (anorthocarbonic hyodeoxycholic acid), nor-LCA (anorthocarbonic lithocholic acid), and nor-HDCA (anorthocarbonic hyodeoxycholic acid).

[0215] 2. Synthesis of oxidative (dehydrogenated) decarbonated bile acid intermediates:

[0216] The oxidized decarboxylated chenodeoxycholic acid intermediate shown below was prepared using nor-CDCA (decarboxylated chenodeoxycholic acid) as a raw material:

[0217]

[0218]

[0219] (1) Preparation of 3-keto-nor-CDCA:

[0220] 10 g of nor-CDCA (anorthochenodeoxycholic acid) raw material was dissolved in 50 mL of toluene, and 1.5 equivalents of freshly prepared silver carbonate / diatomaceous earth were added, and the mixture was heated to 80 degrees to react until the reaction raw material disappeared. After filtration, the mixture was concentrated under reduced pressure, and subjected to silica gel column chromatography or recrystallization to obtain 3-keto-anorthochenodeoxycholic acid with an HPLC purity of >95% and a yield of 75%.

[0221] The obtained 3-keto-anoxochenodeoxycholic acid is further reduced with sodium borohydride, and separated by silica gel column chromatography to obtain two products, one is anoxochenodeoxycholic acid and the other is 3β-anoxochenodeoxycholic acid.

[0222] (2) Preparation of 7-keto-nor-CDCA:

[0223] Dissolve 10 g of nor-CDCA (anorthochenodeoxycholic acid) in 50 mL of acetic acid aqueous solution, add 1.2 equivalents of NBS, and stir at room temperature until the reaction material disappears. Silica gel column chromatography or recrystallization is performed to obtain 7-keto-anorthochenodeoxycholic acid with a HPLC purity of >95% and a yield of 88%.

[0224] (3) Preparation of 3,7-diketo-nor-CDCA:

[0225] Dissolve 10 g of nor-CDCA (anorthochenodeoxycholic acid) raw material in 50 mL of acetone, add 4 equivalents of CrO3, and stir at room temperature until the reaction is complete. Filter and concentrate, then perform silica gel column chromatography or recrystallize to obtain 3,7-diketo-anorthochenodeoxycholic acid with HPLC purity >95% and a yield of 71%.

[0226] (4) Preparation of 3,7-diketo-4-ene-nor-CDCA:

[0227] 10 g of 7-keto-anorthochenodeoxycholic acid raw material was dissolved in 50 mL of toluene, 1.0 equivalent of 2-iodoacylbenzoic acid (IBX) was added, and the reaction was stirred at room temperature until the reaction raw material disappeared, and the TLC detection product spot showed strong fluorescence. Silica gel column chromatography or recrystallization was performed to obtain 3,7-diketo-4-ene-anorthochenodeoxycholic acid with HPLC purity>95%, and the yield was 64%.

[0228] (5) 3,7-dione-1,4-diene-chenodeoxycholic acid

[0229] Preparation of (3 / 7-diketo-1 / 4-diene-nor-CDCA):

[0230] The obtained 3,7-diketo-4-ene-anorthochenodeoxycholic acid is reacted with IBX by the above method to obtain 3,7-diketo-1,4-diene-anorthochenodeoxycholic acid.

[0231] (6) 3-Keto-4-ene-7-acetylated chenodeoxycholic acid

[0232] Preparation of (3-keto-4-ene-7-acetyl-nor-CDCA):

[0233] 10 g of 3-keto-anacetylated chenodeoxycholic acid raw material is reacted with an esterifying agent (e.g., acetic anhydride) to obtain a 7-hydroxyethylated derivative. This derivative is reacted with IBX using the above method to obtain 3-keto-4-ene-7-acetylated anacetylated chenodeoxycholic acid.

[0234] (7) 3-Keto-1, 4-diene-7-acetylated chenodeoxycholic acid

[0235] Preparation of (3-keto-1 / 4-diene-7-acetyl-nor-CDCA):

[0236] The obtained 3-keto-4-ene-7-acetylated anhydrochenodeoxycholic acid derivative is reacted with IBX by the above method to obtain 3-keto-1,4-diene-7-acetylated anhydrochenodeoxycholic acid.

[0237] Referring to the above method for preparing oxidized chenodeoxycholic acid intermediates, the following oxidized chenodeoxycholic acid intermediates were prepared respectively: 3-keto ursodeoxycholic acid (3-keto-nor-UDCA), 3-keto chenodeoxycholic acid (3-keto-nor-CA), 7-keto chenodeoxycholic acid (7-keto-nor-CA), 3-keto lithocholic acid (3-keto-nor-LCA), 3-keto-hyodeoxycholic acid (3-keto-nor-HCA), 3-keto-hyodeoxycholic acid (3-keto-nor-HDCA), and 3,7-diketo-hyodeoxycholic acid (3,7-diketo-nor-HDCA).

[0238]

[0239] 3. Synthesis of other bile acid intermediates:

[0240] The above-mentioned decarbonated cholic acid intermediates are used as raw materials to prepare the decarbonated cholic acid intermediates with the following structure:

[0241]

[0242] (1) Preparation of 3-β-hydroxy-anorthochenodeoxycholic acid (3-β-nor-CDCA):

[0243] The obtained 3-keto-anorthochenodeoxycholic acid is reduced with sodium borohydride, and separated by silica gel column chromatography to obtain two products, one is anorthochenodeoxycholic acid (nor-CDCA) and the other is 3-β-anorthochenodeoxycholic acid (3-β-nor-CDCA).

[0244] (2) Preparation of 3-methoxy-7-keto-nor-CDCA:

[0245] The obtained 7-keto-anoxochenodeoxycholic acid is treated with tetrahydrofuran solvent, sodium cyanide and methyl iodide are added until the raw materials react completely, and ammonium chloride is added to terminate the reaction. 3-methoxy-7-keto-anoxochenodeoxycholic acid is obtained by silica gel column chromatography.

[0246] (3) Preparation of 3-methoxy-nor-CDCA:

[0247] The obtained 3-methoxy-7-keto-anorthochenodeoxycholic acid is reduced with sodium borohydride and separated by silica gel column chromatography to obtain 3-methoxy-anorthochenodeoxycholic acid.

[0248] 4. Synthesis of Thiopheneamine Intermediates:

[0249] (R / S)-1-(thiophene-2)-propylamine (IA-1), (R)-1-(thiophene-2)-propylamine (IA-1-R) and (S)-1-(thiophene-2)-propylamine (IA-1-S) were prepared according to the following synthetic route:

[0250]

[0251] Step 1: After propionic acid (4.42 mmol), trifluoroacetic acid (2.5 mL) and 4.42 mmol of thiophene are mixed, 4.42 mmol of 85% H3PO4 is added dropwise under stirring until the reaction is complete, and poured into ice water to precipitate a white solid.

[0252] Step 2: The solid was dispersed and dissolved in toluene, 2 equivalents of ammonium acetate and 2 equivalents of sodium borocyanide were added, and the reaction was heated until the reaction was complete. After cooling, the reaction was quenched with acid water, the acid water layer was separated, and then the base was adjusted with dilute sodium hydroxide solution, extracted with methyl tert-butyl ether, dried and concentrated, and the residue was crystallized with DL tartaric acid / acetone water system to obtain racemic 1-(thiophene-2)-propylamine tartrate with HPLC purity>98%. The salt was extracted and distributed with ethyl acetate / dilute sodium hydroxide aqueous solution, and the ethyl acetate layer was dried and concentrated to dryness under reduced pressure to obtain a colorless oil, namely (R / S)-1-(thiophene-2)-propylamine (IA-1), with a total yield of 52%.

[0253] Step 3 (chiral separation): The above 14.1g racemic thienylpropylamine (100mmol, 1.0eq) and 70ml of anhydrous ethanol are added to a 250ml three-necked flask, the temperature is raised to 60°C, and the tartaric acid ethanol solution (preparation method: dissolve 15.0g of D-tartaric acid in 70ml of anhydrous ethanol, 1.0eq) is slowly added dropwise to the reaction solution, the temperature is kept at about 60°C, stirred for 0.5 hours, and the temperature is cooled to room temperature. A white solid is precipitated and filtered to obtain 28g of solid (wet product). The solid is repeatedly recrystallized with anhydrous ethanol and dried at 60°C by forced air drying to finally obtain 7.5g of (R)-thienylpropylamine-D-tartrate.

[0254] The above 7.5 g of solid was partitioned with 5% sodium hydroxide solution and ethyl acetate. The ethyl acetate layer was washed with water 1-2 times, dried over anhydrous sodium sulfate and filtered to remove sodium sulfate. The filtrate was concentrated under reduced pressure at 60°C and evaporated to dryness to obtain 3.6 g of (R)-1-(thiophene-2)-propylamine (IA-1-R). HPLC determination of ee>98%.

[0255] All the mother liquors were combined to recover the thiophene propylamine. Then, the same method was used to crystallize (S)-1-(thiophene-2)-propylamine (IA-1-S) using L-tartaric acid. HPLC determination showed that ee was > 98%.

[0256] Referring to the synthesis methods of IA-1, IA-1-R and IA-1-S, the remaining thiophene amine derivatives were prepared by replacing different substituted thiophene raw materials and different acids. For example:

[0257] (R / S)-1-(thiophene-2)-ethylamine (IA-2), (R)-1-(thiophene-2)-ethylamine (IA-2-R), and S-1-(thiophene-2)-ethylamine (IA-2-S);

[0258] (R / S)-1-(5-chloro-thiophene-2)-ethylamine (IA-3), (R)-1-(5-chloro-thiophene-2)-ethylamine (IA-3-R) and S-1-(5-chloro-thiophene-2)-ethylamine (IA-3-S);

[0259] (R / S)-1-(5-bromo-thiophene-2)-ethylamine (IA-4), (R)-1-(5-bromo-thiophene-2)-ethylamine (IA-4-R) and S-1-(5-bromo-thiophene-2)-ethylamine (IA-4-S);

[0260] (R / S)-1-(thiophene-2)-cyclopropylmethylamine (IA-5), (R)-1-(thiophene-2)-cyclopropylmethylamine (IA-5-R), and (S)-1-(thiophene-2)-cyclopropylmethylamine (IA-5-S);

[0261] (R / S)-1-(5-chloro-thiophene-2)-propylamine (IA-6), (R)-1-(5-chloro-thiophene-2)-propylamine (IA-6-R), and (S)-1-(5-chloro-thiophene-2)-propylamine (IA-6-S);

[0262] (R / S)-1-(5-bromo-thiophene-2)-propylamine (IA-7), (R)-1-(5-bromo-thiophene-2)-propylamine (IA-7-R), and (S)-1-(5-bromo-thiophene-2)-propylamine (IA-7-S);

[0263] (R / S)-2-methyl-1-(thiophene-2)-1-propylamine (IA-8), (R)-2-methyl-1-(thiophene-2)-1-propylamine (IA-8-R), and (S)-2-methyl-1-(thiophene-2)-1-propylamine (IA-8-S);

[0264] (R / S)-2-methyl-1-(5-chloro-thiophene-2)-1-propylamine (IA-9), (R)-2-methyl-1-(5-chloro-thiophene-2)-1-propylamine (IA-9-R), and (S)-2-methyl-1-(5-chloro-thiophene-2)-1-propylamine (IA-9-S);

[0265] (R / S)-2-methyl-1-(5-bromo-thiophene-2)-1-propylamine (IA-10), (R)-2-methyl-1-(5-bromo-thiophene-2)-1-propylamine (IA-10-R), and (S)-2-methyl-1-(5-bromo-thiophene-2)-1-propylamine (IA-10-S);

[0266] (R / S)-1-(thiophene-2)-butylamine (IA-11), (R / S)-1-(thiophene-2)-pentylamine (IA-12), (R / S)-1-(thiophene-2)-hexylamine (IA-13), (R / S)-1-(thiophene-2)-octylamine (IA-14), (R / S)-1-(thiophene-2)-dodecylamine (IA-15), (R / S)-1-(thiophene-2)-tetradecylamine (IA-16), (R / S)-1-(thiophene-2)- Cyclopentylmethylamine (IA-17), (R / S)-1-(thiophene-2)-cyclobutylmethylamine (IA-18), (R / S)-1-(thiophene-2)-cyclohexylmethylamine (IA-19), (R / S)-2-dimethyl-1-(thiophene-2)-propylamine (IA-20), (R / S)-1-(thiophene-2)-benzylamine (IA-21), bis-(thiophene-2)-methylamine (IA-22), (R / S)-1-(thiophene-2)-cyclobutylmethylamine (IA-23).

[0267] The raw materials used in the following examples can be prepared by referring to the above method or directly purchased.

[0268] Example 1 Synthesis of Compound I-1

[0269]

[0270] 5.5 g (14.5 mmol) of decarbonated chenodeoxycholic acid (nor-CDCA) was dissolved in 110 ml of DMF, and 1.3 g (18.3 mmol) of cyclopropylmethylamine and 2.3 g (17.8 mmol) of N,N-diisopropylethylamine DIPEA were added. After stirring and dissolving, the mixture was cooled to 0-5 degrees Celsius in an ice-salt bath, and 5.7 g (17.8 mmol) of O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate TBTU was added to the reaction system in portions. After TBTU was completely added, the reaction temperature was maintained at 0-5 degrees Celsius for 1 hour, and then the mixture was heated to room temperature and stirred overnight.

[0271] TLC monitored the complete reaction of the bile acid raw material. The reaction system was added with the same volume of water (110 ml) and ethyl acetate (110 ml) as DMF, and the mixture was allowed to stand for separation. The ethyl acetate layer was washed twice with one-fifth volume (22 ml) of 10% sodium carbonate solution, washed twice with one-fifth volume (22 ml) of 5% hydrochloric acid, and then washed twice with one-fifth volume (22 ml) of saturated brine. The ethyl acetate layer was then dried with 10 g of anhydrous sodium sulfate, the sodium sulfate was removed by filtration, the ethyl acetate was concentrated to dryness, and the residue was purified by silica gel column chromatography to obtain a total of 5.1 g of compound I-1 with a purity of >98% by HPLC, and a yield of 81.7%.

[0272] 1HNMR (CDCl3, 400MHz): δ3.88(s,1H),3.16(s,1H),2.55-2.40(m,1H),2.32-2.13(m,1H),2.05-1.97(m,4H),1.97-1.67(m,11H),1.58-1.36( m,6H),1.35-1.16(m,2H),1.01(d,J=6.4Hz,3H),0.99-0.95(m,1H),0.93(s,3H),0.74(s,3H),0.53(d,J=7.7Hz,2H),0.23(d,J=5.0Hz,2H);

[0273] ESI-MS m / z:430.31[M-1] -

[0274] Example 2 Synthesis of Compound I-2

[0275]

[0276] Using norCDCA and 2-furanmethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-2.

[0277] 1 HNMR (CDCl3, 400MHz): δ7.37 (s, 1H), 6.34 (s, 1H), 6.24 (d, J = 3.1Hz, 1H), 5.82 (t, J = 5.6Hz ,1H),4.46(d,J=5.2Hz,2H),3.87(brs,1H),3.48(tt,J=10.6,4.5Hz,1H),2.42(dd,J=13.9 ,3.5Hz,1H),2.21(q,J=12.5Hz,1H),2.05-1.93(m,3H),1.89-1.59(m,8H),1.57-1.23(m,7 H),1.23-1.09(m,3H),1.07-1.02(m,1H),0.99(d,J=6.5Hz,3H),0.92(s,3H),0.72(s,3H);

[0278] ESI-MS m / z:456.22[M-1] -

[0279] Example 3 Synthesis of Compound I-3

[0280]

[0281] Using nor-CDCA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that in Example 1 to obtain compound I-3.

[0282] 1 HNMR (CDCl3, 400MHz): δ7.25 (d, J = 4.9Hz, 1H), 7.01-6.95 (m, 2H), 5.82 (brs, 1H), 4.64 (t,J=6.1Hz,2H),3.87(d,J=3.2Hz,1H),3.55-3.42(m,1H),2.48-2.39(m,1H),2.29-2. 14(m,1H),2.07-1.95(m,3H),1.94-1.60(m,7H),1.57-1.47(m,3H),1.47-1.25(m,5H), 1.23-1.11(m,3H),1.05-1.03(m,1H),1.01(d,J=6.4Hz,3H),0.93(s,3H),0.73(s,3H);

[0283] ESI-MS m / z:472.28[M-1] -

[0284] Example 4 Synthesis of Compound I-4

[0285]

[0286] Using nor-CDCA and benzylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-4.

[0287] 1 H NMR (CDCl3, 400MHz) δ7.40–7.26(m,5H),5.87(s,1H),4.54–4.40(m,2H),3.87( d,J=3.3Hz,1H),3.55-3.42(m,1H),2.50-2.41(m,1H),2.33–2.14(m,1H),2.12 –1.95(m,4H),1.94–1.81(m,4H),1.78–1.59(m,4H),1.57–1.46(m,3H),1.47–1 .25(m,4H),1.28–1.09(m,3H),1.01(d,J=6.6Hz,3H),0.92(s,3H),0.72(s,3H).

[0288] ESI-MS m / z:466.30[M-1] -

[0289] Example 5 Synthesis of Compound I-5

[0290]

[0291] Using nor-CDCA and 3-aminomethylpyridine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-5.

[0292] ESI-MS m / z:467.32[M-1] -

[0293] Example 6 Synthesis of Compound I-6

[0294]

[0295] Using nor-CDCA and 2-aminomethylpyridine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-6.

[0296] 1 H NMR (CDCl3, 400MHz): δ8.56(d,J=5.0Hz,1H),7.80-7.70(m,1H),7.40–7.33(m,1H),7.32-7.23(m,1H),6.8 5(s,1H),4.61(d,J=5.0Hz,2H),3.87(q,J=3.1Hz,1H),3.55-3.42(m,1H),2.52-2.42(m,1H),2.31-2.15(m, 1H),2.09–1.95(m,4H),1.95-1.78(m,4H),1.57–1.46(m,3H),1.46–1.37(m,2H),1.41–1.31(m,2H),1.34– 1.18(m,2H),1.22–1.09(m,2H),1.00(d,J=6.2Hz,3H),1.06-0.88(m,1H),0.92(s,3H),0.73(s,3H).ESI-MS m / z:467.32[M-1] -

[0297] Example 7 Synthesis of Compound I-7

[0298]

[0299] Using nor-CDCA and 2-thiazolemethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-7.

[0300] 1HNMR (CDCl3, 400MHz): δ7.76-7.70(m,1H),7.37–7.29(m,1H),4.82–4.75(m, 2H),3.87(d,J=3.6Hz,1H),3.54-3.41(m,1H),2.51-2.40(m,1H),2.29-2.15 (m,1H),2.09–1.94(m,3H),1.92–1.79(m,5H),1.76–1.60(m,4H),1.56–1.12 (m,10H),1.01(d,J=6.5Hz,3H),1.05–0.87(m,1H),0.92(s,3H),0.72(s,3H).

[0301] ESI-MS m / z:473.25[M-1] -

[0302] Example 8 Synthesis of Compound I-8

[0303]

[0304] Using nor-CDCA and IA-2 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-8.

[0305] 1 HNMR (CDCl3, 400MHz): δ7.22 (d, J = 4.8Hz, 1H), 7.01-6.94 (m, 2H), 5.73-5.65 (m, 1H), 5.15-5.39 (m, 1H) ),3.87(q,J=3.0Hz,1H),3.55–3.39(m,1H),2.46–2.30(m,1H),2.31–2.14(m,1H),2.09–1.95(m,4H),1 .94–1.80(m,3H),1.79–1.68(m,2H),1.64–1.46(m,5H),1.54(s,3H),1.47–1.37(m,2H),1.39–1.27(m ,1H),1.28(s,3H),1.21-1.12(m,2H),1.06-0.95(m,4H),0.92(s,3H),0.92–0.83(m,1H),0.72(s,3H).

[0306] ESI-MS m / z:486.29[M-1] -

[0307] Example 9 Synthesis of Compound I-9

[0308]

[0309] Using nor-CDCA and α-phenylethylamine as raw materials, the synthesis method is similar to that in Example 1 to obtain compound I-9.

[0310] 1 HNMR (CDCl3, 400MHz): δ7.40–7.24(m,5H),5.76(s,1H),5.17(m,1H),3.86(d,J =3.3Hz,1H),3.55-3.42(m,1H),2.47–2.30(m,1H),2.31-2.14(m,1H),2.12–1.9 3(m,4H),1.89–1.80(m,2H),1.80–1.68(m,4H),1.56–1.41(m,7H),1.44-1.28(m ,5H),1.25-1.10(m,3H),1.06-0.93(m,4H),0.92(s,3H),0.71(d,J=3.7Hz,3H).

[0311] ESI-MS m / z:480.30[M-1] -

[0312] Example 10 Synthesis of Compound I-10

[0313]

[0314] Using nor-UDCA and cyclopropylmethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-10.

[0315] 1 HNMR (CDCl3, 400MHz): δ5.52(s,1H),3.68-3.55(m,2H),3.14(s,2H),2.48 -2.33(m,1H),2.09–1.96(m,2H),1.89–1.54(m,10H),1.56-1.51(m,3H),1. 51–1.37(m,5H),1.34-1.05(m,5H),1.07-0.89(m,1H),1.01(d,J=6.1Hz,3 H),0.97(s,3H),0.75(s,3H),0.52(d,J=7.6Hz,2H),0.22(d,J=4.8Hz,2H).

[0316] ESI-MS m / z:430.30[M-1] -

[0317] Example 11 Synthesis of Compound I-11

[0318]

[0319] Using nor-UDCA and 2-furanmethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-11.

[0320] 1 HNMR (d6-DMSO, 400MHz): δ7.68–7.61(m,2H),7.28(s,1H),6.27–6.20(m,1H),6 .12(d,J=3.1Hz,1H),4.36–4.19(m,2H),3.44-3.33(m,2H),2.30-2.20(m,1H),1 .97-1.87(m,2H),1.86–1.63(m,4H),1.57–1.36(m,4H),1.39–1.19(m,4H),1.2 2–1.05(m,4H),1.08–0.88(m,3H),0.88-0.86(m,4H),0.85(s,3H),0.62(s,3H).

[0321] ESI-MS m / z:456.22[M-1] -

[0322] Example 12 Synthesis of Compound I-12

[0323]

[0324] Using nor-UDCA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-12.

[0325] 1 HNMR (d6-DMSO, 400MHz): δ7.66–7.58(m,1H),7.58-7.52(m,2H),7.17–7.08(m,1H),6.91-6.81(m,2H),4.55–4.38(m,2H),3.46-3.50(m,2H),2. 32–2.21(m,1H),1.97–1.86(m,1H),1.83-1.63(m,3H),1.56-1.44(m,5H ),1.42-1.25(m,6H),1.25–1.10(m,7H),1.10–0.82(m,7H),0.63(s,3H).

[0326] ESI-MS m / z:472.28[M-1] -

[0327] Example 13 Synthesis of Compound I-13

[0328]

[0329] Using 7-keto-nor-CDCA and 2-furanmethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-13.

[0330] 1 HNMR (CDCl3, 400MHz): δ7.37 (s, 1H), 6.37–6.31 (m, 1H), 6.24 (d, J = 3.2Hz, 1H), 5.76 (s,1H),4.46(d,J=5.2Hz,2H),3.68-3.56(m,1H),2.92-2.83(m,1H),2.48–2.36(m, 2H),2.28-2.16(m,1H),2.03–1.85(m,3H),1.85–1.61(m,8H),1.58–1.43(m,3H),1. 47–1.22(m,3H),1.21(s,3H),1.19–0.89(m,3H),0.99(d,J=6.3Hz,3H),0.72(s,3H).

[0331] ESI-MS m / z:454.26[M-1] -

[0332] Example 14 Synthesis of Compound I-14

[0333]

[0334] Using 7-keto-nor-CDCA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that in Example 1 to obtain compound I-14.

[0335] 1 HNMR (CDCl3, 400MHz): δ7.31–7.20(m,1H),7.01–6.93(m,2H),6.17-5.81(m,1H, 4.71–4.56(m,2H),3.67-3.55(m,1H),2.92-2.82(m,1H),2.50–2.36(m,2H),2.2 4-2.14(m,1H),2.10-1.80(m,5H),2.02–1.90(m,2H),1.74–1.65(m,2H),1.56-1 .25(m,6H),1.21(s,3H),1.26–0.92(m,5H),1.00(d,J=6.5Hz,3H),0.72(s,3H).

[0336] ESI-MS m / z:470.28[M-1] -

[0337] Example 15 Synthesis of Compound I-15

[0338]

[0339] Using 7-keto-nor-CDCA and 2-thiazolemethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-15.

[0340] 1 HNMR (CDCl3, 400MHz): δ7.72(d,J=3.2Hz,1H),7.31(d,J=3.3Hz,1H),6.47(s,1H) ,4.78(t,J=5.8Hz,2H),3.68-3.55(m,1H),2.92-2.82(m,1H),2.52–2.36(m,2H), 2.25-2.20(m,1H),2.06-2.96(m,3H),1.96–1.66(m,8H),1.58-1.39(m,3H),1.10 -1.23(m,3H),1.21(s,3H),1.20–1.08(m,3H),1.00(d,J=6.4Hz,3H),0.71(s,3H).

[0341] ESI-MS m / z:471.28[M-1] -

[0342] Example 16 Synthesis of Compound I-16

[0343]

[0344] Using 7-keto-nor-CDCA and 2-aminomethylpyridine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-16.

[0345] 1 HNMR (CDCl3, 400MHz): δ8.55(d,J=4.8Hz,1H),7.70(t,J=6.8Hz,1H),7.37–7.20(m,2H) ,6.82(t,J=5.0Hz,1H),4.62-4.55(m,2H),3.68-3.55(m,1H),2.92-2.82(m,1H),2.53–2 .35(m,2H),2.27–2.14(m,1H),2.08–1.78(m,9H),1.76-1.66(m,2H),1.52–1.43(m,3H) ,1.42–1.22(m,4H),1.21(s,3H),1.21–1.08(m,3H),0.99(d,J=6.4Hz,3H),0.71(s,3H).

[0346] ESI-MS m / z:465.30[M-1] -

[0347] Example 17 Synthesis of Compound I-17

[0348]

[0349] Using nor-CA and 2-furanmethylamine as raw materials, the synthesis method is similar to that in Example 1 to obtain compound I-17.

[0350] 1 HNMR (CDCl3, 400MHz): δ7.37(s,1H),6.34(s,1H),6.25(d,J=3.2Hz,1H),6.09(s,1H),4.50– 4.43(m,2H),4.02(s,1H),3.87(s,1H),3.55-3.44(m,1H),2.49-2.40(m,1H),2.29–2.18(m,2 H),2.19-1.89(m,5H),1.89-1.75(m,2H),1.71-1.66(m,1H),1.63–1.51(m,4H),1.47–1.25(m ,5H),1.24-1.09(m,1H),1.05(d,J=6.3Hz,3H),0.99–0.88(m,1H),0.91(s,3H),0.75(s,3H).

[0351] ESI-MS m / z:472.29[M-1] -

[0352] Example 18 Synthesis of Compound I-18

[0353]

[0354] Using nor-CA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-18.

[0355] 1HNMR (CDCl3, 400MHz): δ7.21 (d, J = 4.9Hz, 1H), 6.99-6.90 (m, 2H), 6.45 (s, 1 H),4.80-4.67(m,2H),4.00(s,1H),3.84(s,1H),3.44(s,1H),2.44-2.35(m ,1H),2.24-2.16(m,2H),1.99-1.62(m,12H),1.61-1.55(m,3H),1.43-1.38 (m,3H),1.18–1.08(m,1H),1.05(,J=6.3Hz,3H),0.90(s,3H),0.73(s,3H).

[0356] ESI-MS m / z:488.25[M-1] -

[0357] Example 19 Synthesis of Compound I-19

[0358]

[0359] Using nor-CA and α-phenylethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-19.

[0360] 1 HNMR (CDCl3, 400MHz): δ7.36–7.22(m,5H),6.38-6.11(m,1H),5.22-5.08(m,1H),3.98(d,J=8.4Hz,1H),3.84(s,1H),3.49-3.38(m,1H),2.42–2 .30(m,1H),2.28–2.15(m,2H),1.98–1.65(m,11H),1.61–1.35(m,8H),1 .35–1.24(m,1H),1.16–0.95(m,5H),0.90(s,3H),0.72(d,J=4.0Hz,3H).

[0361] ESI-MS m / z:496.35[M-1] -

[0362] Example 20 Synthesis of Compound I-20

[0363]

[0364] Using 7-keto-nor-CA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-20.

[0365] 1HNMR (CDCl3, 400MHz): δ7.22 (d, J = 5.1Hz, 1H), 7.00-6.91 (m, 2H), 6.55 (s, 1H), 4.70-4. 52(m,2H),4.03(s,1H),3.62–3.51(m,1H),2.89-2.79(m,1H),2.53–2.30(m,2H),2.31–2 .16(m,2H),2.09–1.78(m,4H),1.77-1.65(m,3H),1.67–1.52(m,2H),1.40-1.18(m,5H) ,1.19(s,3H),1.18–1.09(m,1H),1.05(d,J=6.0Hz,3H),1.05–0.83(m,2H),0.74(s,3H).

[0366] ESI-MS m / z:486.26[M-1] -

[0367] Example 21 Synthesis of Compound I-21

[0368]

[0369] Using nor-HCA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that in Example 1 to obtain compound I-21.

[0370] 1 HNMR (CDCl3, 400MHz): δ7.25–7.18(m,1H),6.98-6.91(m,2H),6.36(s,1H),4.57 (s,2H),3.86(s,2H),3.51-3.40(m,1H),2.47-2.39(m,1H),2.09-1.98(m,2H),1. 90-1.78(m,3H),1.74-1.69(m,5H),1.57-1.45(m,4H),1.43-1.28(m,2H),1.32– 1.14(m,4H),1.11-1.03(m,1H),1.00(d,J=6.3Hz,3H),0.92(s,3H),0.72(s,3H).

[0371] ESI-MS m / z:488.27[M-1] -

[0372] Example 22 Synthesis of Compound I-22

[0373]

[0374] Using nor-HCA and IA-2 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-22.

[0375] 1 HNMR (CDCl3, 400MHz): δ7.23(d,J=5.1Hz,1H),7.04–6.95(m,2H),5.47-5.40(m,1H),3.91-3.84(m,2H),3.51-3.39(m,1H),2.50(s,1H) ,2.30-1.39(m,17H)1.39–1.24(m,2H),1.22-1.16(m,4H),1.11–0.74(m,2H),1.02(d,J=6.3Hz,3H),0.92(s,3H),0.72(d,J=3.5Hz,3H).

[0376] ESI-MS m / z:502.29[M-1] -

[0377] Example 23 Synthesis of Compound I-23

[0378]

[0379] Using 3,7-diketo-nor-CDCA and α-phenylethylamine as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-23.

[0380] 1 HNMR (CDCl3, 400MHz): δ7.41–7.24(m,5H),5.74(s,1H),5.24-5.11(m,1H),2.95-2.85(m,1H),2.57–2.37(m,2H),2.33–2.17(m,6H),2.12–1. 96(m,3H),1.96-1.81(m,4H),1.80–1.42(m,8H),1.45–1.23(m,1H),1. 32(s,3H),1.26-1.08(m,2H),1.04-0.93(m,3H),0.75(d,J=2.8Hz,3H).

[0381] ESI-MS m / z:478.20[M+1] +

[0382] Example 24 Synthesis of Compound I-24

[0383]

[0384] Using 3,7-diketo-nor-CDCA and (S)-α-phenylethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-24.

[0385] 1 HNMR (CDCl3, 400MHz): δ7.39-7.31(m,4H),7.31–7.23(m,1H),5.82(s,1H),5.23-5. 11(m,1H),2.94-2.84(m,1H),2.57–2.38(m,2H),2.32-2.14(m,5H),2.17–1.81(m,6H ),1.81–1.66(m,1H),1.68–1.54(m,2H),1.50(d,J=6.9Hz,3H),1.55–1.34(m,3H),1. 31(s,3H),1.32–1.10(m,3H),1.13–0.95(m,1H),0.94(d,J=6.5Hz,3H),0.74(s,3H).

[0386] ESI-MS m / z:476.17[M-1] -

[0387] Example 25 Synthesis of Compound I-25

[0388]

[0389] Using 3, 7-diketo-nor-CDCA and (R)-α-phenylethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-25.

[0390] 1 HNMR (CDCl3, 400MHz): δ7.41–7.18(m,5H),5.52(s,1H),3.61-3.50(m,2H),2.95-2.79(m,3H),2.52(t,J=11.3Hz,1H),2.41–2.25(m,4H),2.2 5-2.13(m,4H),2.13–2.02(m,2H),2.01-1.83(m,4H),1.75–1.44(m,5H ),1.32(s,3H),1.31–0.93(m,2H),0.96(d,J=6.4Hz,3H),0.74(s,3H).

[0391] ESI-MS m / z:478.33[M+1] +

[0392] Example 26 Synthesis of Compound I-26

[0393]

[0394] Using 3, 7-diketo-nor-CDCA and 2-thiophenemethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-26.

[0395] 1 HNMR (CDCl3, 400MHz): δ7.24(d,J=4.8,1H),7.02-6.94(m,2H),4.73–4.56(m,2H),2.95-2.85(m,1H),2.58–2.40(m,2H),2.33–2.17(m,4H),2. 16–1.85(m,4H),1.84–1.58(m,3H),1.58-1.45(m,2H),1.40-1.12(m,7 H),1.33(s,3H),1.02(d,J=6.4Hz,3H),0.94–0.83(m,2H),0.76(s,3H).

[0396] ESI-MS m / z:468.29[M-1] -

[0397] Example 27 Synthesis of Compound I-27

[0398]

[0399] Using 3, 7-diketo-nor-CDCA and IA-2 as raw materials, the synthesis method is similar to Example 1 to obtain compound I-27.

[0400] 1 HNMR (CDCl3, 400MHz): δ7.22 (d, J = 4.8Hz, 1H), 7.01-6.94 (m, 2H), 5.52-5.40 (m, 1H),2.95-2.85(m,1H),2.58-2.47(m,1H),2.49-2.38(m,1H),2.34–2.17(m,6H) ,2.20–2.03(m,3H),2.05–1.81(m,3H),1.81–1.64(m,2H),1.64–1.45(m,6H),1. 41–1.33(m,1H),1.32(s,3H),1.26–1.10(m,2H),1.05-0.96(m,4H),0.76(s,3H).

[0401] ESI-MS m / z:482.20[M-1] -

[0402] Example 28 Synthesis of Compound I-28

[0403]

[0404] Using 3, 7-diketo-nor-CDCA and IA-2-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-28.

[0405] 1 HNMR (CDCl3, 400MHz): δ7.22 (d, J = 4.8Hz, 1H), 7.00-6.94 (m, 2H), 5.53-5.41 (m, 1H),2.95-2.85(m,1H),2.59-2.49(m,1H),2.50-2.39(m,1H),2.34–2.17(m,6H) ,2.20–2.03(m,3H),2.05–1.81(m,2H),1.81–1.64(m,3H),1.64–1.45(m,6H),1. 41–1.33(m,1H),1.32(s,3H),1.26–1.10(m,2H),1.05-0.96(m,4H),0.76(s,3H).

[0406] ESI-MS m / z:482.20[M-1] -

[0407] Example 29 Synthesis of Compound I-29

[0408]

[0409] Using 3, 7-diketo-nor-CDCA and IA-2-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-29.

[0410] 1 HNMR (CDCl3, 400MHz): δ7.22 (d, J = 4.8Hz, 1H), 7.01-6.94 (m, 2H), 5.51-5.4 0(m,1H),2.95-2.85(m,1H),2.58-2.47(m,1H),2.49-2.38(m,1H),2.35–2. 16(m,6H),2.20–2.03(m,3H),2.04–1.84(m,3H),1.80–1.65(m,2H),1.64–1 .33(m,7H),1.32(s,3H),1.26–1.10(m,2H),1.05-0.96(m,4H),0.76(s,3H).

[0411] ESI-MS m / z:482.20[M-1] -

[0412] Example 30 Synthesis of Compound I-30

[0413]

[0414] Using 3, 7-diketo-nor-CDCA and (R / S)-1-(5-methyl-thiophene-2)ethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-30.

[0415] 1 HNMR (CDCl3, 400MHz): δ6.75 (d, J = 3.4Hz, 1H), 6.60 (s, 1H), 5.72-5.66 (m, 1H), 5. 42-5.27(m,1H),2.95-2.85(m,1H),2.58-2.47(m,1H),2.46(s,3H),2.46–2.37(m, 1H),2.33–2.15(m,5H),2.13-2.04(m,2H),2.01–1.84(m,2H),1.79–1.64(m,2H),1 .64-1.45(m,7H),1.32(s,3H),1.40-0.95(m,5H),1.02-0.98(m,3H),0.76(s,3H).

[0416] ESI-MS m / z:496.26[M-1] -

[0417] Example 31 Synthesis of Compound I-31

[0418]

[0419] Using 3, 7-diketo-nor-CDCA and (R / S)-1-(3-methyl-thiophene-2)ethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-31.

[0420] 1HNMR (CDCl3, 400MHz): δ7.12 (d, J = 5.2 Hz, 1H), 6.83 (d, J = 5.0 Hz, 1H), 5.59 (d, J = 7. 9Hz,1H),5.46(q,J=6.5Hz,1H),2.95-2.85(m,1H),2.57-2.47(m,1H),2.33–2.17(m ,9H),2.15-1.85(m,6H),1.78-1.67(m,2H),1.60–1.45(m,4H),1.41–1.33(m,1H), 1.32(s,3H),1.22–1.08(m,3H),1.08–0.90(m,1H),1.03-0.94(m,3H),0.75(s,3H).

[0421] ESI-MS m / z:496.26[M-1] -

[0422] Example 32 Synthesis of Compound I-32

[0423]

[0424] Using 3,7-diketo-nor-CDCA, IA-3 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-32.

[0425] 1 HNMR (CDCl3, 400MHz): δ6.77-6.71(m,2H),5.80(s,1H),5.38-5.25(m,1H),2.95-2 .85(m,1H),2.57-2.47(m,1H),2.46-2.36(m,1H),2.35-2.15(m,5H),2.15-1.99(m ,3H),2.01–1.80(m,3H),1.82–1.64(m,2H),1.60–1.44(m,6H),1.43–1.32(m,1H), 1.32(s,3H),1.32–1.08(m,3H),1.06-0.92(m,1H),1.02-0.96(m,3H),0.75(s,3H).

[0426] ESI-MS m / z:516.14[M-1] -

[0427] Example 33 Synthesis of Compound I-33

[0428]

[0429] Using 3,7-diketo-nor-CDCA, IA-4 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-33.

[0430] ESI-MS m / z:560.06[M-1] -

[0431] Example 34 Synthesis of Compound I-34

[0432]

[0433] Take 0.3 g (0.62 mmol) of compound I-27 in a 100 ml single-mouth bottle, add 50 ml of acetonitrile to dissolve, slowly add 0.11 g (1.12 mmol) of concentrated sulfuric acid, cool to 10 degrees Celsius in an ice water bath, slowly add 0.37 g (1.76 mmol) of trifluoroacetic anhydride to the system, after the addition is completed, heat the oil bath to 50 degrees Celsius and react for 3 hours.

[0434] TLC detected that the raw material reaction was complete, and 100 ml of water and 100 ml of ethyl acetate were added. The layers were allowed to stand for stratification, and the aqueous layer was extracted once with 100 ml of ethyl acetate. The organic layers were combined and washed once with 50 ml of saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the sodium sulfate was removed by filtration. The ethyl acetate was concentrated and the obtained oil was crystallized with a small amount of ethyl acetate. The compound 0.25 g I-34 was obtained by filtration.

[0435] ESI-MS m / z:562.22[M-1] -

[0436] I-34 can react with various organic or inorganic amines to prepare various corresponding salts.

[0437] Example 35 Synthesis of Compound I-35

[0438]

[0439] Using 3, 7-diketo-nor-CDCA and IA-1 as raw materials, the synthesis method is similar to Example 1 to obtain compound I-35.

[0440] 1HNMR (CDCl3, 400MHz): δ7.25–7.18(m,1H),7.00–6.94(m,2H),5.67(d,J=8.6Hz,1 H),5.25(q,J=7.6Hz,1H),2.95-2.85(m,1H),2.57–2.38(m,2H),2.33–2.18(m,4H ),2.22–2.01(m,4H),2.01–1.87(m,4H),1.84-1.45(m,6H),1.32(s,3H),1.43–1. 21(m,2H),1.24–1.10(m,2H),1.10–0.85(m,1H),1.03–0.97(m,6H),0.75(s,3H).

[0441] ESI-MS m / z:596.33[M-1] -

[0442] Example 36 Synthesis of Compound I-36

[0443]

[0444] Using 3,7-diketo-nor-CDCA, IA-1-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-36.

[0445] 1 HNMR (CDCl3, 400MHz): δ7.25–7.18(m,1H),7.00–6.94(m,2H),5.67(d,J=8.6Hz,1 H),5.25(q,J=7.6Hz,1H),2.96-2.86(m,1H),2.57–2.37(m,2H),2.33–2.18(m,4H ),2.22–2.01(m,4H),2.01–1.87(m,4H),1.84-1.45(m,6H),1.32(s,3H),1.43–1. 21(m,2H),1.24–1.10(m,2H),1.10–0.85(m,1H),1.03–0.97(m,6H),0.75(s,3H).

[0446] ESI-MS m / z:596.33[M-1] -

[0447] Example 37 Synthesis of Compound I-37

[0448]

[0449] Using 3,7-diketo-nor-CDCA, IA-1-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-37.

[0450] 1 HNMR (CDCl3, 400MHz): δ7.25–7.18(m,1H),7.00–6.94(m,2H),5.67(d,J=8.6Hz,1 H),5.25(q,J=7.6Hz,1H),2.94-2.84(m,1H),2.58–2.38(m,2H),2.33–2.18(m,4H ),2.22–2.01(m,4H),2.01–1.87(m,4H),1.84-1.45(m,6H),1.32(s,3H),1.43–1. 21(m,2H),1.24–1.10(m,2H),1.10–0.85(m,1H),1.03–0.97(m,6H),0.75(s,3H).

[0451] ESI-MS m / z:596.33[M-1] -

[0452] Example 38 Synthesis of Compound I-38

[0453]

[0454] Using 3,7-diketo-nor-CDCA, IA-7 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-38.

[0455] 1 HNMR (CDCl3, 400MHz): δ6.90 (d, J = 3.7Hz, 1H), 6.73 (d, J = 3.7Hz, 1H), 5.68-5 .57(m,1H),5.14(q,J=7.6Hz,1H),2.95-2.85(m,1H),2.57–2.38(m,3H),2.34 -2.15(m,7H),2.15–2.03(m,1H),2.01-1.72(m,6H),1.56–1.48(m,3H),1.38- 1.27(m,1H),1.32(s,3H),1.26-1.11(m,2H),1.09–0.94(m,8H),0.75(s,3H).

[0456] ESI-MS m / z:574.17[M-1] -

[0457] Example 39 Synthesis of Compound I-39

[0458]

[0459] Using I-35 as raw material, the synthesis method is similar to Example 34 to obtain compound I-39.

[0460] 1 HNMR (CDCl3, 400MHz): δ7.18(s,1H),6.93(s,2H),5.21–5.14(m,1H),2.94-2.15(m,10H),2.15 -1.70(m,8H),1.70-0.70(m,21H);2.94-2.15(m,10H),2.15-1.70(m,8H),1.70-0.70(m,21H);

[0461] ESI-MS m / z:576.21[M-1] -

[0462] Example 40 Synthesis of Compound I-40

[0463]

[0464] Using 3,7-diketo-nor-CDCA, IA-8 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-40.

[0465] 1 HNMR (CDCl3, 400MHz): δ7.28(s,1H),6.79–6.67(m,2H),5.69(d,J=9.0Hz,1H),5.06–4.97(m,1H),2.95-2.85(m,1H),2.58–2.40(m,2H),2. 36–2.10(m,7H),2.10–1.97(m,3H),1.97-1.74(m,3H),1.74–1.45(m, 6H),1.33(s,3H),1.42–1.10(m,3H),1.10–0.93(m,10H),0.75(s,3H).

[0466] ESI-MS m / z:510.25[M-1] -

[0467] Example 41 Synthesis of Compound I-41

[0468]

[0469] Using 3,7-diketo-nor-CDCA, IA-11 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-41.

[0470] 1 HNMR (CDCl3, 400MHz): δ7.21(d,J=4.8Hz,1H),7.00-6.95(m,2H),5.67(s,1H),5.33(q,J=7.7Hz,1H),2.95-2.85(m,1H),2.57–2.3 7(m,3H),2.33–2.15(m,6H),2.14–1.79(m,8H),1.78–1.33(m,7H),1.32(s,3H),1.26–1.09(m,2H),1.06–0.93(m,7H),0.75(s,3H).

[0471] ESI-MS m / z:510.22[M-1] -

[0472] Example 42 Synthesis of Compound I-42

[0473]

[0474] Using 3,7-diketo-nor-CDCA, IA-12 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-42.

[0475] 1 HNMR (CDCl3, 400MHz): δ7.21 (d, J = 4.7Hz, 1H), 6.99-6.94 (m, 2H), 5.69 (t, J = 8.9H z,1H),5.36-5.26(m,1H),2.94-2.85(m,2H),2.57–2.34(m,3H),2.33–2.14(m,6H ),2.15–1.96(m,4H),1.98–1.87(m,2H),1.82-1.71(m,1H),1.70–1.47(m,4H),1. 32(s,3H),1.51–1.22(m,3H),1.23-1.09(m,2H),1.09–0.82(m,9H),0.75(s,3H).

[0476] ESI-MS m / z:524.32[M-1] -

[0477] Example 43 Synthesis of Compound I-43

[0478]

[0479] Using 3,7-diketo-nor-CDCA, IA-20 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-43.

[0480] 1 HNMR (CDCl3, 400MHz): δ7.21-7.14(m,1H),6.98-6.91(m,2H),5.88-5.77(m, 1H),5.24-5.15(m,1H),2.95-2.85(m,1H),2.57–2.36(m,2H),2.33–2.13(m, 6H),2.14–1.74(m,7H),1.67–1.44(m,3H),1.32(s,3H),1.41–1.16(m,2H),1 .19–1.08(m,2H),1.01(s,9H),0.89(d,J=6.4Hz,3H),0.73(d,J=6.8Hz,3H).

[0481] ESI-MS m / z:524.32[M-1] -

[0482] Example 44 Synthesis of Compound I-44

[0483]

[0484] Using 3,7-diketo-nor-CDCA, IA-13 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-44.

[0485] 1 HNMR (CDCl3, 400MHz): δ7.20(d,J=4.7Hz,1H),6.99-6.93(m,2H),5.82-5.59(m,1H),5.31(q,J=7.7Hz,1H),2.95-2.85(m,1H),2.57–2.37(m,3H) ),2.34-2.12(m,8H),2.11-1.84(m,8H),1.84–1.64(m,2H),1.64-1.44( m,4H),1.32(s,3H),1.23-1.11(m,3H),1.09–0.84(m,9H),0.75(s,3H).

[0486] ESI-MS m / z:538.22[M-1] -

[0487] Example 45 Synthesis of Compound I-45

[0488]

[0489] Using 3,7-diketo-nor-CDCA, IA-14 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-45.

[0490] 1 HNMR (CDCl3, 400MHz): δ7.21 (d, J = 4.6Hz, 1H), 6.96 (s, 2H), 5.80-5.57 (m, 1H),5.31(q,J=7.7Hz,1H),2.95-2.85(m,1H),2.57-2.37(m,2H),2.33–2.1 8(m,2H),2.14–1.79(m,9H),1.70–1.42(m,4H),1.42–1.31(m,4H),1.32(s, 3H),1.35–1.24(m,8H),1.26–1.09(m,2H),1.08–0.84(m,7H),0.75(s,3H).

[0491] ESI-MS m / z:566.35[M-1] -

[0492] Example 46 Synthesis of Compound I-46

[0493]

[0494] Using 3,7-diketo-nor-CDCA, IA-15 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-46.

[0495] ESI-MS m / z:623.41[M-1] -

[0496] Example 47 Synthesis of Compound I-47

[0497]

[0498] Using 3,7-diketo-nor-CDCA, IA-16 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-47.

[0499] 1HNMR (CDCl3, 400MHz): δ7.21(dd,J=4.4,1.8Hz,1H),6.97(s,2H),5.72-5.60(m,1H),5.31(q,J=7.7Hz,1H),2.95-2.85(m,1H),2.57–2.37(m,2H),2 .33–2.15(m,6H),2.15–2.01(m,1H),2.01–1.79(m,5H),1.69–1.45(m,4H ),1.45–1.23(m,27H),1.23–1.09(m,4H),1.07-0.85(m,7H),0.75(s,3H).

[0500] ESI-MS m / z:650.45[M-1] -

[0501] Example 48 Synthesis of Compound I-48

[0502]

[0503] Using 3,7-diketo-nor-CDCA, IA-5 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-48.

[0504] ESI-MS m / z:508.28[M-1] -

[0505] Example 49 Synthesis of Compound I-49

[0506]

[0507] Using 3,7-diketo-nor-CDCA, IA-5-S as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-49.

[0508] ESI-MS m / z:508.28[M-1] -

[0509] Example 50 Synthesis of Compound I-50

[0510]

[0511] Using 3,7-diketo-nor-CDCA, IA-5-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-50.

[0512] ESI-MS m / z:508.28[M-1] -

[0513] Example 51 Synthesis of Compound I-51

[0514]

[0515] Using 3, 7-diketo-nor-CDCA, (R / S)-1-(5-chloro-thiophene-2)-cyclopropylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-51.

[0516] ESI-MS m / z:542.20[M-1] -

[0517] Example 52 Synthesis of Compound I-52

[0518]

[0519] Using compound I-48 as raw material, the synthesis method is similar to Example 34 to obtain compound I-52.

[0520] ESI-MS m / z:611.20[M+Na] +

[0521] Example 53 Synthesis of Compound I-53

[0522]

[0523] Using 3,7-diketo-nor-CDCA, IA-17 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-53.

[0524] ESI-MS m / z:536.29[M-1] -

[0525] Example 54 Synthesis of Compound I-54

[0526]

[0527] Using 3,7-diketo-nor-CDCA, IA-19 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-54.

[0528] 1 HNMR (CDCl3, 400MHz): δ7.20(s,1H),6.96(s,2H),5.64(brs,1H),5.15(m,1H),2.8 9(m,1H),2.68-2.39(m,2H),2.38-1.42(m,20H),1.42-0.80(m,18H),0.75(s,3H);

[0529] ESI-MS m / z:550.28[M-1] -

[0530] Example 55 Synthesis of Compound I-55

[0531]

[0532] Using 3,7-diketo-nor-CDCA, IA-21 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-55.

[0533] 1 HNMR (CDCl3, 400MHz): δ7.42-7.30 (m, 5H), 7.25 (d, J = 5.2Hz, 1H), 6.96 (t, J = 4.4Hz, 1H),6.81(s,1H),6.50(d,J=7.8Hz,1H),6.11(d,J=8.2Hz,1H),2.95-2.85(m,1H),2 .57-2.44(m,2H),2.31–2.18(m,5H),2.15-2.05(m,3H),2.02–1.79(m,4H),1.70–1. 58(m,3H),1.32(s,3H),1.30–1.12(m,4H),1.08-0.96(m,3H),0.75(d,J=2.6Hz,3H).

[0534] ESI-MS m / z:544.30[M-1] -

[0535] Example 56 Synthesis of Compound I-56

[0536]

[0537] Using 3,7-diketo-nor-CDCA, IA-22 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-56.

[0538] 1HNMR (CDCl3, 400MHz): δ7.28 (s, 2H), 7.03-6.95 (m, 4H), 6.78 (d, J = 8.2Hz, 1H), 6 .14(d,J=8.3Hz,1H),2.95-2.85(m,1H),2.57–2.43(m,2H),2.35–2.17(m,5H),2. 15–2.03(m,3H),2.02-1.79(m,4H),1.63-1.51(m,4H),1.51–1.33(m,2H),1.32( s,2H),1.30-1.12(m,3H),1.02(d,J=6.4Hz,3H),1.09–0.84(m,1H),0.76(s,3H).

[0539] ESI-MS m / z:550.23[M-1] -

[0540] Example 57 Synthesis of Compound I-57

[0541]

[0542] Using 3,7-diketo-nor-CDCA, IA-23 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-57.

[0543] ESI-MS m / z:522.31[M-1] -

[0544] Example 58 Synthesis of Compound I-58

[0545]

[0546] Using 3, 7-diketo-nor-CDCA and (R / S)-1-phenylpropan-1-amine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-58.

[0547] 1HNMR (CDCl3, 400MHz): δ7.39–7.23(m,5H),5.73(s,1H),4.92(q,J=7.6Hz,1H),2 .95-2.85(m,1H),2.56-2.46(m,1H),2.46-2.36(m,1H),2.33-2.18(m,4H),2.14- 1.97(m,4H),1.97-1.71(m,4H),1.70-1.43(m,6H),1.32(s,3H),1.22–1.09(m,3 H),1.02(d,J=6.5Hz,3H),0.92(t,J=7.3Hz,3H),1.08-0.88(m,2H),0.75(s,3H).

[0548] ESI-MS m / z:490.30[M-1] -

[0549] Example 59 Synthesis of Compound I-59

[0550]

[0551] Using 3, 7-diketo-nor-CDCA and (S)-1-phenylpropan-1-amine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-59.

[0552] 1 HNMR (CDCl3, 400MHz): δ7.39–7.23(m,5H),5.73(s,1H),4.92(q,J=7.6Hz,1H),2 .95-2.85(m,1H),2.55-2.45(m,1H),2.45-2.35(m,1H),2.35-2.18(m,5H),2.15- 1.95(m,3H),1.96-1.71(m,4H),1.71-1.44(m,6H),1.32(s,3H),1.23–1.09(m,3 H),1.02(d,J=6.5Hz,3H),0.92(t,J=7.3Hz,3H),1.08-0.88(m,2H),0.75(s,3H).

[0553] ESI-MS m / z:490.30[M-1] -

[0554] Example 60 Synthesis of Compound I-60

[0555]

[0556] Using 3, 7-diketo-nor-CDCA and (R)-1-phenylpropan-1-amine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-60.

[0557] 1 HNMR (CDCl3, 400MHz): δ7.39–7.23(m,5H),5.73(s,1H),4.92(q,J=7.6Hz,1H),2 .95-2.85(m,1H),2.57-2.46(m,1H),2.46-2.36(m,1H),2.33-2.18(m,4H),2.14- 1.96(m,4H),1.96-1.71(m,4H),1.71-1.44(m,6H),1.32(s,3H),1.22–1.09(m,3 H),1.02(d,J=6.5Hz,3H),0.92(t,J=7.3Hz,3H),1.08-0.88(m,2H),0.75(s,3H).

[0558] ESI-MS m / z:490.30[M-1] -

[0559] Example 61 Synthesis of Compound I-61

[0560]

[0561] Using 3,7-diketo-nor-CDCA and dibenzhydrylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-61.

[0562] 1 HNMR (CDCl3, 400MHz): δ7.39–7.21 (m, 10H), 6.30 (d, J = 7.8Hz, 1H), 6.12-6.0 0(m,1H),2.95-2.85(m,1H),2.57-2.45(m,2H),2.33–2.20(m,4H),2.20–2.0 5(m,4H),2.05–1.87(m,4H),1.72–1.43(m,4H),1.43–1.33(m,1H),1.32(s,3 H),1.30–1.11(m,3H),1.01(d,J=6.5Hz,3H),1.10–0.91(m,1H),0.75(s,3H).

[0563] ESI-MS m / z:538.30[M-1] -

[0564] Example 62 Synthesis of Compound I-62

[0565]

[0566] Using 3,7-diketo-nor-CDCA and 1,2-diphenylethylamine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-62.

[0567] 1 HNMR (CDCl3, 400MHz): δ7.37–7.15(m,8H),7.10(t,J=7.8Hz,2H),5.74(s,1H), 5.39-5.25(m,1H),3.20-3.04(m,2H),2.95-2.85(m,1H),2.56-2.45(m,1H),2. 40–2.03(m,8H),2.01–1.87(m,2H),1.87–1.66(m,2H),1.66-1.54(m,2H),1.52 -1.42(m,2H),1.32(s,3H),1.34–0.92(m,6H),0.88-0.78(m,3H),0.71(s,3H).

[0568] ESI-MS m / z:552.34[M-1] -

[0569] Example 63 Synthesis of Compound I-63

[0570]

[0571] Using 3,7-diketo-nor-CDCA and 2-amino-2-phenylacetic acid as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-63.

[0572] 1 HNMR (CDCl3, 400MHz): δ7.43–7.33(m,5H),6.62(s,1H),5.60(d,J=6.8Hz,1H),2.94-2.84(m,1H),2.56–2.39(m,2H),2.34–2.16( m,5H),2.17–2.02(m,5H),2.01–1.81(m,5H),1.72-1.54(m,2H),1.32(s,3H),1.24–1.09(m,4H),1.05-0.94(m,4H),0.72(s,3H).

[0573] ESI-MS m / z:506.46[M-1] -

[0574] Example 64 Synthesis of Compound I-64

[0575]

[0576] Using 3,7-diketo-nor-CDCA and 3-amino-3-phenylpropionic acid as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-64.

[0577] 1 HNMR (CDCl3, 400MHz): δ7.39–7.24(m,5H),6.77-6.50(m,1H),5.47(q,J=6.8Hz,1H),4.18-4.10(m,1H),3.05-2.83(m,3H),2.57–2.38(m,2H) ,2.34-2.15(m,6H),2.14-1.96(m,6H),1.96-1.77(m,2H),1.63–1.44( m,3H),1.32(s,3H),1.40–1.11(m,3H),1.09–0.88(m,4H),0.73(s,3H).

[0578] ESI-MS m / z:520.19[M-1] -

[0579] Example 65 Synthesis of Compound I-65

[0580]

[0581] Using 3, 7-diketo-nor-CDCA and 2-aminomethylpyridine as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-65.

[0582] 1 HNMR (CDCl3, 400MHz): δ8.56(d,J=4.9Hz,1H),7.77–7.67(m,1H),7.37-7.20(m,2 H),6.83–6.76(m,1H),4.63-4.56(m,2H),2.95-2.85(m,1H),2.57–2.44(m,2H),2 .30-2.20(m,5H),2.20–1.96(m,4H),1.98–1.84(m,4H),1.73–1.45(m,5H),1.45– 1.31(m,1H),1.32(s,3H),1.27-1.12(m,2H),1.01(d,J=6.5Hz,3H),0.76(s,3H).

[0583] ESI-MS m / z:463.18[M-1] -

[0584] Example 66 Synthesis of Compound I-66

[0585]

[0586] Using 3, 7-diketo-nor-CDCA and IA-8-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-66.

[0587] 1 HNMR (CDCl3, 400MHz): δ7.28(s,1H),6.79–6.67(m,2H),5.81-5.57(m,1H),5.06–4.97(m,1H),2.95-2.86(m,1H),2.58–2.40(m,2H),2.36 –2.10(m,7H),2.10–1.97(m,3H),1.97-1.74(m,3H),1.74–1.45(m,6H),1.33(s,3H),1.42–1.10(m,3H),1.10–0.93(m,10H),0.75(s,3H).

[0588] ESI-MS m / z:510.19[M-1] -

[0589] Example 67 Synthesis of Compound I-67

[0590]

[0591] Using 3, 7-diketo-nor-CDCA and IA-8-S as raw materials, the synthesis method is similar to Example 1 to obtain compound I-67.

[0592] 1 HNMR (CDCl3, 400MHz): δ7.28(s,1H),6.79–6.67(m,2H),5.81-5.57(m,1H),5.07–4.97(m,1H),2.96-2.86(m,1H),2.58–2.38(m,3H),2.38 –2.10(m,6H),2.10–1.97(m,3H),1.97-1.74(m,3H),1.74–1.45(m,6H),1.33(s,3H),1.42–1.10(m,3H),1.10–0.93(m,10H),0.75(s,3H).

[0593] ESI-MS m / z:510.19[M-1] -

[0594] Example 68 Synthesis of Compound I-68

[0595]

[0596] Using 3, 7-diketo-nor-CDCA and IA-6 as raw materials, the synthesis method is similar to Example 1 to obtain compound I-68.

[0597] 1 HNMR (CDCl3, 400MHz): δ6.78-6.70(m,2H),5.71(d,J=8.8Hz,1H),5.10(q,J=7.6Hz,1H),2.95–2.85(m,1H),2.57–2.36(m,3H),2.36–2.14(m,7H) ),2.14–2.01(m,4H),2.01–1.90(m,2H),1.90–1.68(m,3H),1.68–1.44( m,2H),1.32(s,3H),1.30–1.10(m,3H),1.09–0.87(m,7H),0.74(s,3H).

[0598] ESI-MS m / z:530.23[M-1] -

[0599] Example 69 Synthesis of Compound I-69

[0600]

[0601] Using 3, 7-diketo-nor-CDCA and IA-6-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-69.

[0602] 1 HNMR (CDCl3, 400MHz): δ6.78-6.70(m,2H),5.71(d,J=8.8Hz,1H),5.10(q,J=7.6Hz,1H),2.94–2.84(m,1H),2.58–2.38(m,3H),2.36–2.14(m,8H) ),2.14–2.01(m,3H),2.01–1.90(m,2H),1.90–1.68(m,3H),1.68–1.44( m,2H),1.32(s,3H),1.30–1.10(m,3H),1.09–0.87(m,7H),0.74(s,3H).

[0603] ESI-MS m / z:554.22[M+Na] +

[0604] Example 70 Synthesis of Compound I-70

[0605]

[0606] Using 3, 7-diketo-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to Example 1 to obtain compound I-70.

[0607] 1 HNMR (CDCl3, 400MHz): δ6.78-6.70(m,2H),5.71(d,J=8.8Hz,1H),5.10(q,J=7.6Hz,1H),2.95–2.85(m,1H),2.57–2.37(m,3H),2.36–2.14(m,8H) ),2.14–2.01(m,3H),2.01–1.90(m,2H),1.90–1.68(m,3H),1.68–1.44( m,2H),1.32(s,3H),1.30–1.10(m,3H),1.09–0.87(m,7H),0.74(s,3H).

[0608] ESI-MS m / z:554.22[M+Na] +

[0609] Example 71 Synthesis of Compound I-71

[0610]

[0611] Using 3, 7-diketo-nor-CDCA and IA-7-S as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-71.

[0612] 1 HNMR (CDCl3, 400MHz): δ6.91(d,J=3.7Hz,1H),6.73(d,J=3.8,1H),5.62(s,1H),5.14(q,J=7.7Hz,1H),2.95-2.85(m,1H),2.58–2.38(m,2H), 2.36–2.16(m,6H),2.16–2.03(m,4H),2.03–1.70(m,5H),1.70-1.50(m ,5H),1.33(s,3H),1.30–1.12(m,2H),1.15–0.94(m,7H),0.76(s,3H).

[0613] ESI-MS m / z:598.10[M+Na] +

[0614] Example 72 Synthesis of Compound I-72

[0615]

[0616] Using 3, 7-diketo-nor-CDCA and IA-7-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-72.

[0617] 1 HNMR (CDCl3, 400MHz): δ6.91(d,J=3.7Hz,1H),6.73(d,J=3.8,1H),5.62(s,1H),5.14(q,J=7.7Hz,1H),2.96-2.86(m,1H),2.58–2.38(m,2H), 2.35–2.15(m,6H),2.15–2.03(m,4H),2.03–1.71(m,5H),1.70-1.50(m ,5H),1.33(s,3H),1.30–1.12(m,2H),1.15–0.94(m,7H),0.76(s,3H).

[0618] ESI-MS m / z:598.10[M+Na] +

[0619] Example 73 Synthesis of Compound I-73

[0620]

[0621] Using compound I-36 as raw material, the synthesis method is similar to Example 34 to obtain compound I-73.

[0622] ESI-MS m / z:599.14[M+Na] +

[0623] Example 74 Synthesis of Compound I-74

[0624]

[0625] Using compound I-37 as raw material, the synthesis method is similar to Example 34 to obtain compound I-74.

[0626] ESI-MS m / z:599.140[M+Na] +

[0627] Example 75 Synthesis of Compound I-75

[0628]

[0629] Using 3, 7-diketo-nor-CDCA and IA-9 as raw materials, the synthesis method is similar to Example 1 to obtain compound I-75.

[0630] 1 HNMR (CDCl3, 400MHz): δ6.79–6.67(m,2H),5.71(s,1H),5.07-4.96(m,1H),2.95-2.85(m,1H),2.58–2.40(m,2H),2.36–2.20(m,5H), 2.20–2.06(m,3H),2.06–1.74(m,4H),1.71–1.45(m,6H),1.32(s,3H),1.44–1.14(m,3H),1.14–0.85(m,10H),0.75(d,J=4.0Hz,3H).

[0631] ESI-MS m / z:568.22[M+Na] +

[0632] Example 76 Synthesis of Compound I-76

[0633]

[0634] Using 3, 7-diketo-nor-CDCA and IA-9-S as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-76.

[0635] 1 HNMR (CDCl3, 400MHz): δ6.79–6.67(m,2H),5.71(s,1H),5.07-4.96(m,1H),2.85-2.86(m,1H),2.58–2.40(m,2H),2.36–2.20(m, 5H),2.20–2.06(m,3H),2.06–1.74(m,4H),1.71–1.45(m,6H),1.32(s,3H),1.44–1.14(m,3H),1.14–0.85(m,10H),0.74(s,3H).

[0636] ESI-MS m / z:568.22[M+Na] +

[0637] Example 77 Synthesis of Compound I-77

[0638]

[0639] Using 3, 7-diketo-nor-CDCA and IA-9-R as raw materials, the synthesis method is similar to Example 1 to obtain compound I-77. 1 HNMR (CDCl3, 400MHz): δ6.79–6.67(m,2H),5.71(s,1H),5.07-4.96(m,1H),2.95-2.85(m,1H),2.58–2.41(m,2H),2.36–2.20(m, 6H),2.20–2.06(m,3H),2.06–1.74(m,4H),1.71–1.45(m,5H),1.32(s,3H),1.44–1.14(m,3H),1.14–0.85(m,10H),0.75(s,3H).

[0640] ESI-MS m / z:568.22[M+Na] +

[0641] Example 78 Synthesis of Compound I-78

[0642]

[0643] Using 3, 7-diketo-nor-CDCA and IA-10 as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-78. 1 HNMR (CDCl3, 400MHz): δ6.90(d,J=3.7Hz,1H),6.73–6.66(m,1H),5.75(s,1H),5.09-4.99(m,1H),2.95-2.86(m,1H),2.58–2.40(m,2H),2.35-2 .21(m,6H),2.21–1.74(m,9H),1.74–1.55(m,2H),1.56-1.25(m,2H),1. 32(s,3H),1.26–1.11(m,2H),1.10–0.91(m,10H),0.75(d,J=4.0Hz,3H).

[0644] ESI-MS m / z:612.14[M+Na] +

[0645] Example 79 Synthesis of Compound I-79

[0646]

[0647] Using 3, 7-diketo-nor-CDCA and IA-10-S as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-79. 1HNMR (CDCl3, 400MHz): δ6.90(d,J=3.7Hz,1H),6.73–6.66(m,1H),5.75(s,1H),5.09-4.99(m,1H),2.96-2.86(m,1H),2.58–2.40(m,2H),2. 35-2.17(m,7H),2.17–1.74(m,8H),1.74–1.55(m,2H),1.56-1.25(m, 2H),1.32(s,3H),1.26–1.11(m,2H),1.10–0.91(m,10H),0.74(s,3H).

[0648] ESI-MS m / z:612.14[M+Na] +

[0649] Example 80 Synthesis of Compound I-80

[0650]

[0651] Using 3, 7-diketo-nor-CDCA and IA-10-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-80. 1 HNMR (CDCl3, 400MHz): δ6.90 (d, J = 3.8 Hz, 1H), 6.69 (d, J = 3.8, 1H), 5.68 (s, 1H), 5.0 9-5.00(m,1H),2.95-2.86(m,1H),2.58-2.48(m,1H),2.48-2.40(m,1H),2.33-2.17( m,6H),2.17–2.07(m,3H),2.07–1.90(m,3H),1.90–1.74(m,2H),1.74–1.59(m,1H), 1.63–1.45(m,3H),1.33(s,3H),1.42–1.12(m,3H),1.15–0.93(m,10H),0.75(s,3H).

[0652] ESI-MS m / z:612.14[M+Na] +

[0653] Example 81 Synthesis of Compound I-81

[0654]

[0655] Using I-40 as the starting material, the synthesis method is similar to that of Example 34 to obtain compound I-81.

[0656] ESI-MS m / z:613.14[M+Na]+

[0657] Example 82 Synthesis of Compound I-82

[0658]

[0659] Using I-67 as raw material, the synthesis method is similar to Example 34 to obtain compound I-82.

[0660] ESI-MS m / z:613.14[M+Na] +

[0661] Example 83 Synthesis of Compound I-83

[0662]

[0663] Using I-66 as the starting material, the synthesis method is similar to that of Example 34 to obtain compound I-83.

[0664] ESI-MS m / z:613.14[M+Na] +

[0665] Example 84 Synthesis of Compound I-84

[0666]

[0667] Using 3-keto-nor-CDCA and IA-1 as raw materials, the synthesis method is similar to Example 1 to obtain compound I-84.

[0668] 1 HNMR (CDCl3, 400MHz): δ7.25–7.19(m,1H),6.97(s,2H),5.64(brs,1H),5.25(q,J=7.6Hz,1H),3.97–3.91(m,1H),3.46-3. 34(m,1H),2.48-2.35(m,2H),2.26-1.74(m,10H),1.74-1.34(m,10H),1.27-1.12(m,4H),1.05-0.95(m,9H),0.76(s,3H).

[0669] ESI-MS m / z:498.11[M-1] -

[0670] Example 85 Synthesis of Compound I-85

[0671]

[0672] Using 3-keto-nor-CDCA and IA-5 as raw materials, the synthesis method is similar to Example 1 to obtain compound I-85.

[0673] 1 HNMR (CDCl3, 400MHz): δ7.23 (d, J = 5.1Hz, 1H), 7.06 (s, 1H), 6.98 (t, J = 4.4Hz, 1H), 5.89-5 .80(m,1H),4.75(t,J=8.9Hz,1H),3.95(s,1H),3.46-3.34(m,1H),2.50-2.35(m,2H),2.2 6–2.12(m,2H),2.11-1.92(m,5H),1.85-1.74(m,2H),1.62-1.36(m,10H),1.33–1.16(m,5 H),1.06(d,J=6.4Hz,2H),1.03(s,3H),0.77(s,3H),0.79-0.67(m,2H),0.67–0.44(m,2H).

[0674] ESI-MS m / z:410.13[M-1] -

[0675] Example 86 Synthesis of Compound I-86

[0676]

[0677] Using 3-keto-nor-CDCA and IA-6 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-86.

[0678] 1 HNMR (d6-DMSO, 400MHz): δ8.25(d,J=8.3Hz,1H), 6.94(d,J=3.8Hz,1H), 6.82-6.76(m, 1H),4.92-4.81(m,1H),4.41-4.36(m,1H),3.69(s,1H),3.47–3.35(m,1H),2.43-2.29( m,1H),2.34-2.14(m,1H),2.01-1.88(m,5H),1.88-1.74(m,5H),1.74–1.61(m,4H),1. 53-1.38(m,4H),1.38–1.17(m,3H),1.17–0.98(m,2H),0.97–0.78(m,9H),0.67(s,3H).

[0679] ESI-MS m / z:532.14[M-1] -

[0680] Example 87 Synthesis of Compound I-87

[0681]

[0682] Using 3-keto-nor-CDCA and IA-6-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-87.

[0683] 1 HNMR (d6-DMSO, 400MHz): δ8.25(d,J=8.3Hz,1H), 6.94(d,J=3.8Hz,1H), 6.80(d,J=3.8Hz ,1H),4.93-4.80(m,1H),4.38(d,J=3.6Hz,1H),3.69(s,1H),3.45–3.35(m,1H),2.43-2. 29(m,1H),2.35-2.15(m,1H),2.01-1.88(m,5H),1.88-1.74(m,5H),1.74–1.61(m,4H),1 .53-1.38(m,4H),1.38–1.17(m,3H),1.17–0.98(m,2H),0.97–0.78(m,9H),0.67(s,3H).

[0684] ESI-MS m / z:532.14[M-1] -

[0685] Example 88 Synthesis of Compound I-88

[0686]

[0687] Using 3-keto-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-88.

[0688] 1HNMR (d6-DMSO, 400MHz): δ8.25(d,J=8.3Hz,1H), 6.94(d,J=3.8Hz,1H), 6.79(d,J=3.8Hz ,1H),4.92-4.81(m,1H),4.38(d,J=3.6Hz,1H),3.69(s,1H),3.47–3.35(m,1H),2.43-2. 29(m,1H),2.34-2.14(m,1H),2.01-1.88(m,5H),1.88-1.74(m,5H),1.74–1.61(m,4H),1 .53-1.38(m,4H),1.38–1.17(m,3H),1.17–0.98(m,2H),0.97–0.78(m,9H),0.67(s,3H).

[0689] ESI-MS m / z:532.14[M-1] -

[0690] Example 89 Synthesis of Compound I-89

[0691]

[0692] Using 3-keto-nor-CDCA and IA-7 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-89.

[0693] 1 HNMR (CDCl3, 400MHz): δ6.94-6.88(m,1H),6.76-6.70(m,1H),5.14(q,J=7.7Hz,1H),3.94(s,1H),3.46-3.33(m,1H) ),2.49-2.35(m,2H),2.27–2.11(m,2H),2.11–1.71(m,10H),1.70–1.12(m,11H),1.05–0.87(m,10H),0.76(s,3H).

[0694] ESI-MS m / z:575.86[M-1] -

[0695] Example 90 Synthesis of Compound I-90

[0696]

[0697] Using 3-keto-nor-CDCA and IA-7-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-90.

[0698] 1HNMR (CDCl3, 400MHz): δ6.91(d,J=3.8Hz,1H),6.73(d,J=3.7Hz,1H),5.13(q,J=7.7Hz,1H),3.94(s,1H),3.48-3.35( m,1H),2.48-2.35(m,2H),2.25–2.11(m,2H),2.12–1.71(m,9H),1.71–1.12(m,12H),1.05–0.87(m,10H),0.76(s,3H).

[0699] ESI-MS m / z:575.86[M-1] -

[0700] Example 91 Synthesis of Compound I-91

[0701]

[0702] Using 3-keto-nor-CDCA and IA-7-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-91.

[0703] 1 HNMR (CDCl3, 400MHz): δ6.91(d,J=3.8Hz,1H),6.73(d,J=3.7Hz,1H),5.14(q,J=7.7Hz,1H),3.94(s,1H),3.47-3.34( m,1H),2.48-2.35(m,2H),2.26–2.11(m,2H),2.11–1.71(m,9H),1.71–1.12(m,12H),1.05–0.87(m,10H),0.76(s,3H).

[0704] ESI-MS m / z:575.86[M-1] -

[0705] Example 92 Synthesis of Compound I-92

[0706]

[0707] Using compound I-84 as raw material, the synthesis method is similar to Example 34 to obtain compound I-92.

[0708] ESI-MS m / z:601.14[M+Na] +

[0709] Example 93 Synthesis of Compound I-93

[0710]

[0711] Using compound I-132 as raw material, the synthesis method is similar to Example 34 to obtain compound I-93.

[0712] ESI-MS m / z:601.14[M+Na] +

[0713] Example 94 Synthesis of Compound I-94

[0714]

[0715] Using compound I-133 as raw material, the synthesis method is similar to Example 34 to obtain compound I-94.

[0716] ESI-MS m / z:601.14[M+Na] +

[0717] Example 95 Synthesis of Compound I-95

[0718]

[0719] Using 3-keto-nor-CDCA and IA-9 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-95.

[0720] 1 HNMR (CDCl3, 400MHz): δ6.80–6.68(m,2H),5.69(s,1H),5.07–4.97(m,1H),3.94(q,J=3.0Hz,1H),3.47-3.34(m,1H),2.48-2.36(m,2H),2. 27–2.13(m,2H),2.13–1.92(m,7H),1.84–1.74(m,3H),1.71–1.32(m, 7H),1.32–1.14(m,1H),1.21(s,3H),1.05–0.92(m,12H),0.76(s,3H).

[0721] ESI-MS m / z:570.24[M+Na] +

[0722] Example 96 Synthesis of Compound I-96

[0723]

[0724] Using 3-keto-nor-CDCA and IA-9-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-96.

[0725] 1 HNMR (CDCl3, 400MHz): δ6.78–6.68(m,2H),5.69(s,1H),5.06–4.96(m,1H),3.94(q,J=3.0Hz,1H),3.47-3.34(m,1H),2.48-2.35(m,2H),2. 27–2.13(m,2H),2.13–1.92(m,7H),1.83–1.73(m,3H),1.71–1.32(m, 7H),1.32–1.14(m,1H),1.21(s,3H),1.05–0.92(m,12H),0.76(s,3H).

[0726] ESI-MS m / z:570.24[M+Na] +

[0727] Example 97 Synthesis of Compound I-97

[0728]

[0729] Using 3-keto-nor-CDCA and IA-9-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-97.

[0730] 1 HNMR (CDCl3, 400MHz): δ6.79–6.68(m,2H),5.69(s,1H),5.06–4.97(m,1H),3.94(q,J=3.0Hz,1H),3.47-3.34(m,1H),2.48-2.35(m,2H),2. 27–2.13(m,2H),2.13–1.92(m,7H),1.84–1.73(m,3H),1.71–1.32(m, 7H),1.32–1.14(m,1H),1.21(s,3H),1.05–0.92(m,12H),0.76(s,3H).

[0731] ESI-MS m / z:570.24[M+Na] +

[0732] Example 98 Synthesis of Compound I-98

[0733]

[0734] Using 3-keto-nor-CDCA and IA-10 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-98.

[0735] 1HNMR (CDCl3, 400MHz):

[0736] ESI-MS m / z:613.13[M+Na] +

[0737] Example 99 Synthesis of Compound I-99

[0738]

[0739] Using 3-keto-nor-CDCA and IA-10-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-99.

[0740] 1 HNMR (CDCl3, 400MHz):

[0741] ESI-MS m / z:613.13[M+Na] +

[0742] Example 100 Synthesis of Compound I-100

[0743]

[0744] Using 3-keto-nor-CDCA and IA-10-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-100.

[0745] 1 HNMR (CDCl3, 400MHz):

[0746] ESI-MS m / z:613.13[M+Na] +

[0747] Example 101 Synthesis of Compound I-101

[0748]

[0749] Using compound I-134 as raw material, the synthesis method is similar to Example 34 to obtain compound I-101.

[0750] ESI-MS m / z:615.15[M+Na] +

[0751] Example 102 Synthesis of Compound I-102

[0752]

[0753] Using compound I-135 as raw material, the synthesis method is similar to Example 34 to obtain compound I-102.

[0754] ESI-MS m / z:615.15[M+Na] +

[0755] Example 103 Synthesis of Compound I-103

[0756]

[0757] Using compound I-136 as raw material, the synthesis method is similar to that of Example 34 to obtain compound I-103.

[0758] ESI-MS m / z:615.15[M+Na] +

[0759] Example 104 Synthesis of Compound I-104

[0760]

[0761] 0.6 g of compound I-86 (1.12 mmol) was placed in a 100 ml single-mouth bottle, 30 ml of pyridine was added, and the temperature was cooled to -15 degrees Celsius in an ice-salt bath. 0.45 g of chlorosulfonic acid (3.86 mmol) was slowly added dropwise while stirring. After the addition was completed, the temperature was slowly raised to room temperature and the reaction was continued for 24 hours. After TLC detection of complete reaction, 100 ml of saturated brine and 20 ml of 30% dilute hydrochloric acid were added and stirred for 1 minute. 70 ml of ethyl acetate and 30 ml of methanol were added, stirred for 1 minute, and allowed to stand for stratification. The organic phase was retained, and the aqueous phase was extracted twice with a mixture of 35 ml of ethyl acetate and 15 ml of methanol. The organic phases were combined and dried over anhydrous sodium sulfate. The sodium sulfate was removed by filtration and the organic phase was concentrated under reduced pressure to obtain a foamy solid, which was compound I-104.

[0762] 1 HNMR (d6-DMSO, 400MHz): δ8.30-8.23(m,1H),6.97-6.91(m,1H),6.80(d,J=3 .8Hz,1H),4.87(q,J=8.0Hz,1H),4.17(s,1H),3.30-3.19(m,1H),2.39-2.29( m,1H),2.25–2.16(m,2H),2.03–1.88(m,7H),1.85-1.79(m,3H),1.76-1.65(m ,3H),1.54–1.39(m,3H),1.37-1.15(m,6H),0.98–0.82(m,10H),0.67(s,3H).

[0763] ESI-MS m / z:615.15[M-1] -

[0764] Take 0.1 g of compound I-104, dissolve it in 10 ml of a mixed solution of ethanol / water (2:1), add sodium hydroxide solution, concentrate the solvent to dryness, redissolve it in 10 ml of ethanol, add 10 ml of methyl tert-butyl ether, precipitate a white solid, filter it and dry it to obtain the sodium salt I-104-1 of compound I-104, the structure of which is as follows:

[0765]

[0766] Example 105 Synthesis of Compound I-105

[0767]

[0768] Using compound I-87 as raw material, the synthesis method is similar to Example 104 to obtain compound I-105.

[0769] 1 HNMR (d6-DMSO, 400MHz): δ8.26 (d, J = 8.4Hz, 1H), 6.94 (d, J = 3.8Hz, 1H), 6.78 (d ,J=3.8Hz,1H),4.87(q,J=8.0Hz,1H),4.17(s,1H),3.29-3.19(m,1H),2.38-2. 28(m,1H),2.25–2.15(m,2H),2.03–1.87(m,7H),1.84-1.79(m,3H),1.76-1.65 (m,3H),1.54–1.39(m,3H),1.39-1.15(m,6H),0.98–0.82(m,10H),0.67(s,3H).

[0770] ESI-MS m / z:615.15[M-1] -

[0771] Compound I-105 was prepared into sodium salt I-105-1 according to the method described in Example 104, and its structure is as follows:

[0772]

[0773] Example 106 Synthesis of Compound I-106

[0774]

[0775] Using compound I-88 as raw material, the synthesis method is similar to that of Example 104 to obtain compound I-106.

[0776] 1HNMR (d6-DMSO, 400MHz): δ8.27(d,J=8.4Hz,1H),6.94(d,J=3.8Hz,1H),6.79(d ,J=3.8Hz,1H),4.87(q,J=8.0Hz,1H),4.17(s,1H),3.30-3.18(m,1H),2.39-2. 28(m,1H),2.25–2.16(m,2H),2.03–1.88(m,7H),1.84-1.79(m,3H),1.75-1.65 (m,3H),1.54–1.39(m,3H),1.37-1.15(m,6H),0.98–0.82(m,10H),0.67(s,3H).

[0777] ESI-MS m / z:615.15[M-1] -

[0778] Compound I-106 was prepared into sodium salt I-106-1 according to the method described in Example 104, and its structure is as follows:

[0779]

[0780] Example 107 Synthesis of Compound I-107

[0781]

[0782] Using compound I-89 as raw material, the synthesis method is similar to that of Example 104 to obtain compound I-107.

[0783] 1 HNMR (d6-DMSO, 400MHz): δ8.30-8.23(m,1H),7.04(d,J=3.8Hz,1H),6.80- 6.74(m,1H),4.92-4.84(m,1H),4.17(s,1H),3.30–3.18(m,1H),2.27-2.17 (m,2H),2.04-1.90(m,6H),1.86-1.76(m,4H),1.73-1.68(m,3H),1.49-1. 43(m,3H),1.38–1.16(m,4H),0.96(s,3H),0.92-0.84(m,9H),0.67(s,3H).

[0784] ESI-MS m / z:656.06[M-1] -

[0785] Compound I-107 was prepared into sodium salt I-107-1 according to the method described in Example 104, and its structure is as follows:

[0786]

[0787] Example 108 Synthesis of Compound I-108

[0788]

[0789] Using compound I-90 as raw material, the synthesis method is similar to Example 104 to obtain compound I-108.

[0790] 1 HNMR (d6-DMSO, 400MHz): δ8.28(d,J=8.5Hz,1H),7.04(s,1H),6.77(s,1H),4.92-4.84(m,1H),4.17(s,1H),3.31–3.19(m,1H),2.26-2.16(m,2H) ),2.04-1.90(m,6H),1.87-1.75(m,4H),1.75-1.67(m,3H),1.48-1.43( m,3H),1.37–1.17(m,4H),0.96(s,3H),0.92-0.84(m,9H),0.66(s,3H).

[0791] ESI-MS m / z:656.06[M-1] -

[0792] Compound I-108 was prepared into sodium salt I-108-1 according to the method described in Example 104, and its structure is as follows:

[0793]

[0794] Example 109 Synthesis of Compound I-109

[0795]

[0796] Using compound I-91 as raw material, the synthesis method is similar to that of Example 104 to obtain compound I-109.

[0797] 1HNMR (d6-DMSO, 400MHz): δ8.27(d,J=8.5Hz,1H),7.04(s,1H),6.77(s,1H),4.92-4.84(m,1H),4.17(s,1H),3.30–3.18(m,1H),2.25-2.17(m,2H) ),2.04-1.90(m,6H),1.87-1.76(m,4H),1.73-1.68(m,3H),1.48-1.43( m,3H),1.37–1.16(m,4H),0.96(s,3H),0.92-0.84(m,9H),0.67(s,3H).

[0798] ESI-MS m / z:656.06[M-1] -

[0799] Compound I-109 was prepared into sodium salt I-109-1 according to the method described in Example 104, and its structure is as follows:

[0800]

[0801] Example 110 Synthesis of Compound I-110

[0802]

[0803] Using compound I-95 as raw material, the synthesis method is similar to Example 104 to obtain compound I-110.

[0804] 1 HNMR (d6-DMSO, 400MHz): δ8.26-8.18(m,1H),6.94(d,J=3.8Hz,1H),6.82-6.76( m,1H),4.82-4.73(m,1H),4.17(s,1H),3.31–3.18(m,1H),2.40-2.67(m,1H),2. 25-2.16(m,2H),2.11–1.88(m,7H),1.91-1.65(m,6H),1.65–1.15(m,7H),1.14- 1.02(m,1H),0.96(s,3H),0.93–0.85(m,7H),0.83(d,J=6.7Hz,3H),0.66(s,3H).

[0805] ESI-MS m / z:626.14[M-1] -

[0806] Compound I-110 was prepared into sodium salt I-110-1 according to the method described in Example 104, and its structure is as follows:

[0807]

[0808] Example 111 Synthesis of Compound I-111

[0809]

[0810] Using compound I-96 as raw material, the synthesis method is similar to that of Example 104 to obtain compound I-111.

[0811] 1 HNMR (d6-DMSO, 400MHz): δ8.21(d,J=8.8Hz,1H), 6.94(d,J=3.8Hz,1H), 6.79(d,J=3.8 Hz,1H),4.81-4.71(m,1H),4.17(s,1H),3.31–3.18(m,1H),2.40-2.67(m,1H),2.25-2. 16(m,2H),2.11–1.88(m,7H),1.91-1.78(m,3H),1.78-1.65(m,3H),1.65–1.38(m,3H), 1.38–1.02(m,5H),0.96(s,3H),0.93–0.85(m,7H),0.83(d,J=6.7Hz,3H),0.66(s,3H).

[0812] ESI-MS m / z:626.14[M-1] -

[0813] Compound I-111 was prepared into sodium salt I-111-1 according to the method described in Example 104, and its structure is as follows:

[0814]

[0815] Example 112 Synthesis of Compound I-112

[0816]

[0817] Using compound I-97 as raw material, the synthesis method is similar to Example 104 to obtain compound I-112.

[0818] 1HNMR (d6-DMSO, 400MHz): δ8.22(d,J=8.8Hz,1H), 6.94(d,J=3.8Hz,1H), 6.79(d,J=3.8Hz,1H ),4.78(t,J=8.2Hz,1H),4.17(s,1H),3.31–3.18(m,1H),2.40-2.67(m,1H),2.25-2.16(m,2H ),2.11–1.88(m,7H),1.91-1.79(m,3H),1.77-1.65(m,3H),1.65–1.38(m,3H),1.38–1.15(m ,4H),1.14-1.02(m,1H),0.96(s,3H),0.93–0.85(m,7H),0.83(d,J=6.7Hz,3H),0.66(s,3H).

[0819] ESI-MS m / z:626.14[M-1] -

[0820] Compound I-112 was prepared into sodium salt I-112-1 according to the method described in Example 104, and its structure is as follows:

[0821]

[0822] Example 113 Synthesis of Compound I-113

[0823]

[0824] Using compound I-98 as raw material, the synthesis method is similar to that of Example 104 to obtain compound I-113.

[0825] 1 HNMR (CD3OD, 400MHz): δ6.98-6.92(m,1H),6.79-6.73(m,1H),4.87-4.80(m,1H),4.54–4.43(m,1H),3.63-3.55(m,1H),3.47-3.35 (m,1H),2.42–2.22(m,3H),2.20-2.01(m,8H),2.01–1.57(m,7H),1.57–1.15(m,6H),1.08(s,3H),1.05–0.89(m,10H),0.77(s,3H).

[0826] ESI-MS m / z:670.15[M-1] -

[0827] Compound I-113 was prepared into sodium salt I-113-1 according to the method described in Example 104, and its structure is as follows:

[0828]

[0829] Example 114 Synthesis of Compound I-114

[0830]

[0831] Using compound I-99 as raw material, the synthesis method is similar to that of Example 104 to obtain compound I-114.

[0832] 1 HNMR (CD3OD, 400MHz): δ6.95(d,J=3.8Hz,1H),6.75(d,J=3.8Hz,1H),4.84(d,J=8.4Hz,1H),4.54–4.44(m,1H),3.58(t,J=6.5Hz,1H),3.47-3.35(m ,1H),2.42–2.21(m,3H),2.21-2.01(m,8H),2.01–1.77(m,4H),1.77–1.56 (m,3H),1.56–1.15(m,6H),1.08(s,3H),1.05–0.89(m,10H),0.77(s,3H).

[0833] ESI-MS m / z:670.15[M-1] -

[0834] Compound I-114 was prepared into sodium salt I-114-1 according to the method described in Example 104, and its structure is as follows:

[0835]

[0836] Example 115 Synthesis of Compound I-115

[0837]

[0838] Using compound I-100 as raw material, the synthesis method is similar to Example 104 to obtain compound I-115.

[0839] 1HNMR (CD3OD, 400MHz): δ6.95(d,J=3.8Hz,1H),6.76(d,J=3.8Hz,1H),4.84(d,J=8.4Hz,1H),4.54–4.43(m,1H),3.59(t,J=6.5Hz,1H),3.47-3.35(m ,1H),2.42–2.22(m,3H),2.20-2.01(m,8H),2.01–1.77(m,4H),1.77–1.56 (m,3H),1.57–1.15(m,6H),1.08(s,3H),1.05–0.89(m,10H),0.77(s,3H).

[0840] ESI-MS m / z:670.15[M-1] -

[0841] Compound I-115 was prepared into sodium salt I-115-1 according to the method described in Example 104, and its structure is as follows:

[0842]

[0843] Example 116 Synthesis of Compound I-116

[0844]

[0845] Using nor-HCA and IA-1 as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-116.

[0846] 1 HNMR (CDCl3, 400MHz): δ7.26–7.19(m,1H),7.00-6.95(m,2H),5.74(S,1H),5.28-5.19(m,1H)3.86(s,2H),2.39-2.20(m,4H),2.10-1 .80(m,5H),1.74-1.69(m,6H),1.57-1.45(m,4H),1.43-1.28(m,2H),1.32–1.14(m,4H),1.12-0.94(m,7H),0.92(s,3H),0.66(s,3H).

[0847] ESI-MS m / z:516.18[M-1] -

[0848] Example 117 Synthesis of Compound I-117

[0849]

[0850] Using nor-HCA and IA-6-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-117.

[0851] 1 HNMR (CDCl3, 400MHz): δ6.80–6.71(m,2H),5.74(s,1H),5.14-5.03(m,1H),3.91-3.84(m,2H),3.52–3.37(m,1H),2.38-2.24(m,4H),2.1 8–2.04(m,5H),2.02-1.79(m,3H),1.75–1.64(m,5H),1.54-1.47(m,3H),1.43–1.12(m,4H),1.12–0.94(m,7H),0.93(s,3H),0.66(s,3H).

[0852] ESI-MS m / z:550.22[M-1] -

[0853] Example 118 Synthesis of Compound I-118

[0854]

[0855] Using nor-HCA and IA-7 as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-118.

[0856] ESI-MS m / z:594.10[M-1] -

[0857] Example 119 Synthesis of Compound I-119

[0858]

[0859] Using nor-HCA and IA-8 as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-119.

[0860] 1HNMR (CDCl3, 400MHz): δ7.24-7.16(m,1H),6.99–6.91(m,2H),5.89(s,1H),5.18 -5.01(m,1H),3.90-3.84(m,2H),3.52-3.41(m,1H),2.47–2.06(m,2H),2.09–1.8 7(m,4H),1.89–1.79(m,2H),1.78–1.63(m,5H),1.53-1.46(m,3H),1.40–1.21(m ,3H),1.24–1.12(m,4H),1.13–0.89(m,10H),0.92(s,3H),0.65(d,J=2.5Hz,3H).

[0861] ESI-MS m / z:530.22[M-1] -

[0862] Example 120 Synthesis of Compound I-120

[0863]

[0864] Using nor-HCA and IA-9-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-120.

[0865] ESI-MS m / z:564.16[M-1] -

[0866] Example 121 Synthesis of Compound I-121

[0867]

[0868] Using nor-HCA and IA-10-S as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-121.

[0869] ESI-MS m / z:608.21[M-1] -

[0870] Example 122 Synthesis of Compound I-122

[0871]

[0872] Using 3-keto-nor-HCA and IA-1-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-122.

[0873] ESI-MS m / z:514.23[M-1] -

[0874] Example 123 Synthesis of Compound I-123

[0875]

[0876] Using 3-keto-nor-HCA and IA-6-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-123.

[0877] ESI-MS m / z:548.23[M-1] -

[0878] Example 124 Synthesis of Compound I-124

[0879]

[0880] Using 3-keto-nor-HCA and IA-6-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-124.

[0881] ESI-MS m / z:592.16[M-1] -

[0882] Example 125 Synthesis of Compound I-125

[0883]

[0884] Using nor-HDCA and IA-1 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-125.

[0885] 1 HNMR (CDCl3, 400MHz): δ7.25-7.18(m,1H),7.01–6.94(m,2H),5.67(s,1H), 5.30-5.20(m,1H),4.13-4.03(m,1H),3.70-3.58(m,1H),2.47-2.39(m,1H) ,2.04-1.87(m,5H),1.84-1.76(m,6H),1.75-1.57(m,3H),1.50–1.22(m,6H ),1.26–1.08(m,6H),1.08–0.94(m,7H),0.93(s,3H),0.70(d,J=3.1Hz,3H).

[0886] ESI-MS m / z:500.17[M-1] -

[0887] Example 126 Synthesis of Compound I-126

[0888]

[0889] Using nor-HDCA and IA-6 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-126.

[0890] 1 HNMR (CDCl3, 400MHz): δ6.79-6.71(m,2H),5.66(s,1H),5.16-5.05(m,1H),4.13-4.03(m,1H),3.71-3.58(m,1H),2.46–2.32(m,1H),2.03–1. 95(m,4H),1.95-1.59(m,9H),1.52-1.36(m,4H),1.29–1.15(m,2H),1. 15-1.08(m,5H),1.08–0.74(m,7H),0.93(s,3H),0.70(d,J=2.9Hz,3H).

[0891] ESI-MS m / z:534.19[M-1] -

[0892] Example 127 Synthesis of Compound I-127

[0893]

[0894] Using nor-HDCA and IA-8 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-127.

[0895] 1 HNMR (CDCl3, 400MHz): δ7.24–7.17(m,1H),7.00-6.92(m,2H),5.69(s,1H),5.21-5.10(m,1H),4.13-4.03(m,1H),3.71-3.58 (m,1H),2.44–2.22(m,2H),2.04–1.87(m,6H),1.84-1.60(m,9H),1.47–1.05(m,9H),1.05–0.88(m,12H),0.73-0.67(m,3H).

[0896] ESI-MS m / z:514.26[M-1] -

[0897] Example 128 Synthesis of Compound I-128

[0898]

[0899] Using nor-HDCA and IA-10-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-128.

[0900] ESI-MS m / z:592.11[M-1] -

[0901] Example 129 Synthesis of Compound I-129

[0902]

[0903] Using 3-keto-nor-HDCA and IA-6-S as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-129.

[0904] ESI-MS m / z:531.07[M-1] -

[0905] Example 130 Synthesis of Compound I-130

[0906]

[0907] Using 3-keto-nor-HDCA and IA-10 as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-130.

[0908] ESI-MS m / z:590.20[M-1] -

[0909] Example 131 Synthesis of Compound I-131

[0910]

[0911] Using 3,6-diketo-nor-HDCA and IA-9-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-131.

[0912] ESI-MS m / z:544.19[M-1] -

[0913] Example 132 Synthesis of Compound I-132

[0914]

[0915] Using 3-keto-nor-CDCA and IA-1-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-132.

[0916] 1HNMR (CDCl3, 400MHz): δ7.25–7.19(m,1H),9.00-6.94(m,2H),5.64(brs,1H),5.25(q,J=7.6Hz,1H),3.94(s,1H),3.45-3. 34(m,1H),2.48-2.35(m,2H),2.26-1.74(m,10H),1.74-1.34(m,10H),1.27-1.12(m,4H),1.05-0.95(m,9H),0.76(s,3H).

[0917] ESI-MS m / z:498.11[M-1] -

[0918] Example 133 Synthesis of Compound I-133

[0919]

[0920] Using 3-keto-nor-CDCA and IA-1-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-133.

[0921] 1 HNMR (CDCl3, 400MHz): δ7.25–7.19(m,1H),6.96(s,2H),5.64(brs,1H),5.25(q,J=7.6Hz,1H),3.97–3.91(m,1H),3.46-3. 35(m,1H),2.48-2.36(m,2H),2.27–1.74(m,10H),1.74-1.33(m,10H),1.27–1.12(m,4H),1.05–0.95(m,9H),0.76(s,3H).

[0922] ESI-MS m / z:498.11[M-1] -

[0923] Example 134 Synthesis of Compound I-134

[0924]

[0925] Using 3-keto-nor-CDCA and IA-8 as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-134.

[0926] 1HNMR (CDCl3, 400MHz): δ7.24-7.17(m,1H),7.00–6.91(m,2H),5.70(s,1H),5. 17(t,J=8.1Hz,1H),3.98-3.91(m,1H),3.47-3.34(m,1H),2.50-2.35(m,2H),2 .27–2.16(m,2H),2.16–1.92(m,7H),1.91–1.73(m,2H),1.62–1.51(m,2H),1. 51-1.36(m,4H),1.38–1.15(m,4H),1.06–0.91(m,13H),0.75(d,J=4.9Hz,3H).

[0927] ESI-MS m / z:512.13[M-1] -

[0928] Example 135 Synthesis of Compound I-135

[0929]

[0930] Using 3-keto-nor-CDCA and IA-8-S as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-135.

[0931] 1 HNMR (CDCl3, 400MHz): δ7.24-7.16(m,1H),7.00-6.90(m,2H),5.70(s,1H),5.21-5.12(m,1H),3.98-3.90(m,1H),3.47-3.34(m,1H),2.50-2.35( m,2H),2.26–2.16(m,2H),2.16–1.91(m,7H),1.91–1.73(m,2H),1.62–1. 38(m,6H),1.38–1.15(m,4H),1.06–0.91(m,13H),0.75(d,J=4.9Hz,3H).

[0932] ESI-MS m / z:512.13[M-1] -

[0933] Example 136 Synthesis of Compound I-136

[0934]

[0935] Using 3-keto-nor-CDCA and IA-8-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-136.

[0936] 1 HNMR (CDCl3, 400MHz): δ7.25-7.18(m,1H),7.01–6.91(m,2H),5.71(s,1H),5. 17(t,J=8.1Hz,1H),3.99-3.90(m,1H),3.47-3.34(m,1H),2.50-2.35(m,2H),2 .26–2.16(m,2H),2.16–1.92(m,7H),1.93–1.73(m,2H),1.62–1.52(m,2H),1. 51-1.36(m,4H),1.36–1.15(m,4H),1.06–0.91(m,13H),0.75(d,J=4.9Hz,3H).

[0937] ESI-MS m / z:512.13[M-1] -

[0938] Example 137 Synthesis of Compound I-137

[0939]

[0940] Using nor-CDCA and IA-6-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-137.

[0941] 1 HNMR (CDCl3, 400MHz): δ6.79–6.70(m,2H),5.73(d,J=8.5Hz,1H),5.10(q,J=7.6Hz,1H),3.90-3.83(m,1H),3.55-3.42(m,1H),2.46-2.37(m,1H ),2.31–2.14(m,1H),2.12-1.96(m,4H),1.96–1.61(m,7H),1.57–1.45( m,3H),1.45–1.08(m,10H),1.06-0.94(m,7H),0.92(s,3H),0.72(s,3H).

[0942] ESI-MS m / z:535.11[M-1] -

[0943] Example 138 Synthesis of Compound I-138

[0944]

[0945] Using nor-CDCA and IA-7-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-138.

[0946] 1 HNMR (CDCl3, 400MHz): δ6.89 (d, J=3.8Hz, 1H), 6.75–6.69 (d, J=3.7Hz, 1H), 5.8 5-5.78(m,1H),5.12(q,J=7.7Hz,1H),3.90-3.82(m,1H),3.54-3.42(m,1H),2. 45-2.33(m,1H),2.29-2.14(m,1H),2.09–1.92(m,5H),1.92–1.62(m,6H),1.57 -1.45(m,4H),1.45–1.09(m,8H),1.06-0.94(m,7H),0.92(s,3H),0.71(s,3H).

[0947] ESI-MS m / z:578.20[M-1] -

[0948] Example 139 Synthesis of Compound I-139

[0949]

[0950] Using nor-CDCA and IA-9-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-139.

[0951] ESI-MS m / z:548.10[M-1] -

[0952] Example 140 Synthesis of Compound I-140

[0953]

[0954] Using nor-CDCA and IA-10-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-140.

[0955] ESI-MS m / z:592.03[M-1] -

[0956] Example 141 Synthesis of Compound I-141

[0957]

[0958] Using nor-UDCA and IA-6-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-141.

[0959] ESI-MS m / z:535.11[M-1] -

[0960] Example 142 Synthesis of Compound I-142

[0961]

[0962] Using nor-UDCA and IA-10-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-142.

[0963] ESI-MS m / z:592.03[M-1] -

[0964] Example 143 Synthesis of Compound I-143

[0965]

[0966] Using 3-β-nor-CDCA and IA-7-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-143.

[0967] 1 HNMR (CDCl3, 400MHz): δ6.90 (d, J = 3.7 Hz, 1H), 6.69 (d, J = 3.7, 1H), 5.65-5.57 (m ,1H),5.10–5.00(m,1H),4.12-4.06(m,1H),3.92-3.85(m,1H),2.53–2.38(m,2H) ,2.12–1.96(m,4H),1.87–1.60(m,6H),1.59–1.41(m,5H),1.45–1.28(m,2H),1. 32–1.17(m,4H),1.21–1.08(m,2H),1.06–0.94(m,7H),0.97(s,3H),0.73(s,3H).

[0968] ESI-MS m / z:578.20[M-1] -

[0969] Example 144 Synthesis of Compound I-144

[0970]

[0971] Using 3-β-nor-CDCA and IA-9-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-144.

[0972] 1HNMR (CDCl3, 400MHz): δ6.79–6.67(m,2H),5.64-5.57(m,1H),5.07-4.98(m,1H),4.12-4.06(m,1H),3.92-3.85(m,1H),2.53 –2.39(m,2H),2.11-1.96(m,4H),1.87–1.71(m,6H),1.71–1.34(m,7H),1.34–1.18(m,7H),1.05–0.86(m,12H),0.73(s,3H).

[0973] ESI-MS m / z:548.10[M-1] -

[0974] Example 145 Synthesis of Compound I-145

[0975]

[0976] Using nor-CA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-145.

[0977] ESI-MS m / z:550.18[M-1] -

[0978] Example 146 Synthesis of Compound I-146

[0979]

[0980] Using nor-CA and IA-9-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-146.

[0981] ESI-MS m / z:564.22[M-1] -

[0982] Example 147 Synthesis of Compound I-147

[0983]

[0984] Using nor-LCA and IA-7-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-147.

[0985] ESI-MS m / z:562.12[M-1] -

[0986] Example 148 Synthesis of Compound I-148

[0987]

[0988] Using nor-LCA and IA-10-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-148.

[0989] ESI-MS m / z:577.12[M-1] -

[0990] Example 149 Synthesis of Compound I-149

[0991]

[0992] Using 7-keto-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-149.

[0993] ESI-MS m / z:532.05[M-1] -

[0994] Example 150 Synthesis of Compound I-150

[0995]

[0996] Using 7-keto-nor-CDCA and IA-9-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-150.

[0997] ESI-MS m / z:546.03[M-1] -

[0998] Example 151 Synthesis of Compound I-151

[0999]

[1000] Using 3, 7-diketo-4-ene-nor-CDCA and IA-7-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-151.

[1001] ESI-MS m / z:572.00[M-1] -

[1002] Example 152 Synthesis of Compound I-152

[1003]

[1004] Using 3, 7-diketo-4-ene-nor-CDCA and IA-10-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-152.

[1005] ESI-MS m / z:586.11[M-1] -

[1006] Example 153 Synthesis of Compound I-153

[1007]

[1008] Using 3,7-diketo-1,4-diene-nor-CDCA and IA-6-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-153.

[1009] ESI-MS m / z:526.07[M-1] -

[1010] Example 154 Synthesis of Compound I-154

[1011]

[1012] Using 3,7-diketo-1,4-diene-nor-CDCA and IA-9-R as raw materials, the synthesis method was similar to that in Example 1 to obtain compound I-154.

[1013] ESI-MS m / z:540.06[M-1] -

[1014] Example 155 Synthesis of Compound I-155

[1015]

[1016] Using 3-keto-4-ene-7-acetyl-nor-CDCA and IA-7-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-155-1 and I-155-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-155-1 is shown in the above reaction formula,

[1017] ESI-MS m / z:616.22[M-1] -

[1018] The structure of compound I-155-2 is shown below:

[1019]

[1020] 1HNMR (CDCl3, 400MHz): δ6.80–6.71(m,2H),5.74(s,1H),5.09(q,J=7.7Hz,1H),3.91-3.85(m,2H),3.52–3.42(m,1H),2.38-2.24(m,1H),2. 18–2.04(m,4H),2.02-1.79(m,6H),1.75–1.64(m,4H),1.54-1.47(m, 3H),1.43–1.12(m,4H),1.12–0.94(m,7H),0.93(s,3H),0.66(s,3H).

[1021] ESI-MS m / z:576.46[M-1] -

[1022] Example 156 Synthesis of Compound I-156

[1023]

[1024] Using 3-keto-4-ene-7-acetyl-nor-CDCA and IA-10-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-156-1 and I-156-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-156-1 is shown in the above reaction formula,

[1025] ESI-MS m / z:530.22[M-1] -

[1026] The structure of compound I-156-2 is shown below:

[1027]

[1028] ESI-MS m / z:576.46[M-1] -

[1029] Example 157 Synthesis of Compound I-157

[1030]

[1031] Using 3-keto-4-ene-7-acetyl-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-157-1 and I-157-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-157-1 is shown in the above reaction formula,

[1032] ESI-MS m / z:572.11[M-1] -

[1033] The structure of compound I-157-2 is shown below:

[1034]

[1035] ESI-MS m / z:530.08[M-1] -

[1036] Example 158 Synthesis of Compound I-158

[1037]

[1038] Using 3-keto-4-ene-7-acetyl-nor-CDCA and IA-9-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-158-1 and I-158-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-158-1 is shown in the above reaction formula,

[1039] ESI-MS m / z:586.06[M-1] -

[1040] The structure of compound I-158-2 is shown below:

[1041]

[1042] ESI-MS m / z:544.09[M-1] -

[1043] Example 159 Synthesis of Compound I-159

[1044]

[1045] Using 3-keto-1, 4-diene-7-acetyl-nor-CDCA and IA-7-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-159-1 and I-159-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-159-1 is shown in the above reaction formula,

[1046] ESI-MS m / z:614.20[M-1] -

[1047] The structure of compound I-159-2 is shown below:

[1048]

[1049] ESI-MS m / z:572.15[M-1] -

[1050] Example 160 Synthesis of Compound I-160

[1051]

[1052] Using 3-keto-1, 4-diene-7-acetyl-nor-CDCA and IA-10-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-160-1 and I-160-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-160-1 is shown in the above reaction formula,

[1053] ESI-MS m / z:628.20[M-1] -

[1054] The structure of compound I-160-2 is shown below:

[1055]

[1056] ESI-MS m / z:586.08[M-1] -

[1057] Example 161 Synthesis of Compound I-161

[1058]

[1059] Using 3-keto-1, 4-diene-7-acetyl-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-161-1 and I-161-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-161-1 is shown in the above reaction formula,

[1060] ESI-MS m / z:570.11[M-1] -

[1061] The structure of compound I-161-2 is shown below:

[1062]

[1063] ESI-MS m / z:528.06[M-1] -

[1064] Example 162 Synthesis of Compound I-162

[1065]

[1066] Using 3-keto-1, 4-diene-7-acetyl-nor-CDCA and IA-9-R as raw materials, the synthesis method is similar to that of Example 1, and the compounds I-162-1 and I-162-2 are obtained by separation and purification by silica gel column chromatography, wherein the structure of compound I-162-1 is shown in the above reaction formula,

[1067] 1 HNMR (CDCl3, 400MHz): δ7.13-7.05(m,1H),6.80–6.71(m,2H),6.32-6.24(m, 1H),6.03(s,1H),5.62-5.55(m,1H),5.16–5.03(m,2H),2.68–2.62(m,2H),2 .42-2.30(m,3H),2.02(s,3H),1.98–1.67(m,6H),1.67–1.53(m,4H),1.53–1 .21(m,3H),1.27(s,3H),1.25–1.11(m,2H),1.06–0.92(m,6H),0.80(s,3H).

[1068] ESI-MS m / z:584.13[M-1] -

[1069] The structure of compound I-161-2 is shown below:

[1070]

[1071] ESI-MS m / z:542.08[M-1] -

[1072] Example 163 Synthesis of Compound I-163

[1073]

[1074] Using 3-keto-nor-UDCA and IA-6-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-163.

[1075] ESI-MS m / z:532.15[M-1] -

[1076] Example 164 Synthesis of Compound I-164

[1077]

[1078] Using 3-keto-nor-UDCA and IA-9-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-164.

[1079] ESI-MS m / z:546.23[M-1] -

[1080] Example 165 Synthesis of Compound I-165

[1081]

[1082] Using 3-keto-nor-CA and IA-7-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-165.

[1083] ESI-MS m / z:592.00[M-1] -

[1084] Example 166 Synthesis of Compound I-166

[1085]

[1086] Using 3-keto-nor-CA and IA-10-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-166.

[1087] ESI-MS m / z:606.13[M-1] -

[1088] Example 167 Synthesis of Compound I-167

[1089]

[1090] Using 3-methoxy-7-keto-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-167.

[1091] ESI-MS m / z:546.03[M-1] -

[1092] Example 168 Synthesis of Compound I-168

[1093]

[1094] Using 3-methoxy-7-keto-nor-CDCA and IA-9-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-168.

[1095] ESI-MS m / z:560.10[M-1] -

[1096] Example 169 Synthesis of Compound I-169

[1097]

[1098] Using 3-methoxy-nor-CDCA and IA-6-R as raw materials, the synthesis method is similar to that of Example 1 to obtain compound I-169.

[1099] ESI-MS m / z:548.12[M-1] -

[1100] Example 170 Synthesis of Compound I-170

[1101]

[1102] Using 3-methoxy-nor-CDCA and IA-9-R as raw materials, the synthesis method was similar to that of Example 1 to obtain compound I-170.

[1103] 1 HNMR (CDCl3, 400MHz): δ6.78–6.67(m,2H),5.82-5.62(m,1H),5.05-4.96( m,1H),3.85(s,1H),3.36(s,3H),3.10-2.97(m,1H),2.47-2.38(m,1H),2. 22–1.93(m,4H),1.90–1.71(m,6H),1.71–1.58(m,2H),1.58-1.45(m,3H), 1.45-1.11(m,9H),1.03-0.87(m,9H),0.92(s,3H),0.71(d,J=1.6Hz,3H).

[1104] ESI-MS m / z:462.20[M-1] -

[1105] Example 171 Synthesis of Compound I-171

[1106]

[1107] 0.5 g of compound I-149 was dissolved in 10 ml of methanol, and 1.5 g of ammonium acetate and 0.75 g of sodium cyanoborohydride were added. The mixture was heated in an oil bath and refluxed for 16 hours until the raw material completely disappeared. 50 ml of 3% potassium carbonate aqueous solution and 50 ml of ethyl acetate were added to the reaction system. After sufficient stirring, the system was allowed to stand for stratification. The aqueous phase was extracted twice with 15 ml of ethyl acetate, the organic layers were combined and washed twice with 20 ml of water, the organic layer was dried over 5 g of anhydrous sodium sulfate, the sodium sulfate was removed by filtration, and the filtrate was concentrated to dryness to obtain a light yellow solid, namely compound I-171.

[1108] ESI-MS m / z:533.06[M-1] -

[1109] Example 172 Synthesis of Compound I-172

[1110]

[1111] Take 0.2 g of compound I-171 and dissolve it in 5 ml of dichloromethane. Take another 0.16 g of PCC and dissolve it in 5 ml of dichloromethane. Add the dichloromethane solution of PCC dropwise into the dichloromethane solution of compound I-171 at room temperature. Stir the reaction at room temperature for 3 hours until the raw material disappears completely. After concentration, separate by column chromatography to obtain compound I-172.

[1112] ESI-MS m / z:531.19[M-1] -

[1113] Example 173 Synthesis of Compound I-173

[1114]

[1115] Using compound I-150 as raw material, the synthesis method is similar to Example 171 to obtain compound I-173.

[1116] ESI-MS m / z:547.16[M-1] -

[1117] Example 174 Synthesis of Compound I-174

[1118]

[1119] Using compound I-173 as raw material, the synthesis method is similar to Example 172 to obtain compound I-174.

[1120] ESI-MS m / z:545.10[M-1] -

[1121] Example 175 Synthesis of Compound I-175

[1122]

[1123] Take 0.5 g of compound I-88 and dissolve it in 5 ml of dichloromethane, add 0.3 g of triethylamine, 0.1 g of DMAP, cool it to 0-4 degrees Celsius in an ice bath, add 0.2 g of acetic anhydride dropwise, remove the ice bath after the addition is complete, and continue to react for 3 hours until the raw material point disappears. Add 40 ml of dichloromethane and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of dichloromethane, combine the organic layers, wash twice with 10 ml of 0.1M hydrochloric acid, and wash once with water, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The obtained product is refined by silica gel column chromatography to obtain compound I-175.

[1124] ESI-MS m / z:574.10[M-1] -

[1125] Example 176 Synthesis of Compound I-176

[1126]

[1127] Using compound I-91 as raw material, the synthesis method is similar to Example 175 to obtain compound I-176.

[1128] ESI-MS m / z:618.12[M-1] -

[1129] Example 177 Synthesis of Compound I-177

[1130]

[1131] Using compound I-97 as raw material, the synthesis method is similar to Example 175 to obtain compound I-177.

[1132] ESI-MS m / z:588.24[M-1] -

[1133] Example 178 Synthesis of Compound I-178

[1134]

[1135] Using compound I-100 as raw material, the synthesis method is similar to Example 175 to obtain compound I-178.

[1136] ESI-MS m / z:632.06[M-1] -

[1137] Example 179 Synthesis of Compound I-179

[1138]

[1139] Take 0.5 g of compound I-88 and dissolve it in 5 ml of dichloromethane, add 0.25 g of pyridine, 0.1 g of DMAP, 0.2 g of succinic anhydride, and reflux at 40 degrees Celsius for 10 hours until the raw materials react completely. Add 40 ml of dichloromethane and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of dichloromethane, combine the organic layers, wash twice with 10 ml of 0.1M hydrochloric acid, and wash once with water, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The obtained product is refined by silica gel column chromatography to obtain compound I-179.

[1140] ESI-MS m / z:632.11[M-1] -

[1141] Example 180 Synthesis of Compound I-180

[1142]

[1143] Using compound I-91 as the starting material, the synthesis method was similar to Example 179 to obtain compound I-180

[1144] ESI-MS m / z:676.08[M-1] -

[1145] Example 181 Synthesis of Compound I-181

[1146]

[1147] Using compound I-97 as the starting material, the synthesis method was similar to Example 179 to obtain compound I-181

[1148] 1 HNMR (CDCl3, 400MHz): δ6.79–6.68(m,2H),6.27(s,1H),5.08–4.97(m,2H),3.03-2.92(m,1H),2.80–2.50(m,3H),2.50–2.35(m, 4H),2.26-2.18(m,3H),2.16-1.78(m,9H),1.73-1.40(m,4H),1.40-1.13(m,5H),1.05(s,3H),1.13-0.86(m,10H),0.72(s,3H).

[1149] ESI-MS m / z:646.12[M-1] -

[1150] Example 182 Synthesis of Compound I-182

[1151]

[1152] Using compound I-100 as the starting material, the synthesis method is similar to Example 179 to obtain compound I-182.

[1153] ESI-MS m / z:690.11[M-1] -

[1154] Example 183 Synthesis of Compound I-183

[1155]

[1156] Take 0.5 g of compound I-88, dissolve it in 5 ml of dichloromethane, add 0.5 g of pyridine, and cool it to 5 degrees Celsius in an ice-water bath; dissolve 0.25 g of octanoyl chloride in 3 ml of dichloromethane, slowly add it dropwise to the reaction system, remove the ice-water bath after the addition is complete, and naturally rise to room temperature, heat and reflux at 40 degrees Celsius for 16 hours until the raw material reacts completely. Add 40 ml of dichloromethane and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of dichloromethane, combine the organic layers, wash twice with 10 ml of 0.1M hydrochloric acid, and wash once with water, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The obtained product is refined by silica gel column chromatography to obtain compound I-183.

[1157] ESI-MS m / z:658.18[M-1] -

[1158] Example 184 Synthesis of Compound I-184

[1159]

[1160] Using compound I-91 as raw material, the synthesis method is similar to Example 183 to obtain compound I-184.

[1161] ESI-MS m / z:702.13[M-1] -

[1162] Example 185 Synthesis of Compound I-185

[1163]

[1164] Using compound I-97 as raw material, the synthesis method is similar to Example 183 to obtain compound I-185.

[1165] ESI-MS m / z:672.19[M-1] -

[1166] Example 186 Synthesis of Compound I-186

[1167]

[1168] Using compound I-100 as raw material, the synthesis method is similar to Example 183 to obtain compound I-186.

[1169] ESI-MS m / z:716.24[M-1] -

[1170] Example 187 Synthesis of Compound I-187

[1171]

[1172] Take 0.3 g of monomethyl suberate and dissolve it in 5 ml of tetrahydrofuran, add 0.2 g of pyridine, and drop 0.2 g of dichlorothionyl at room temperature. After the addition is completed, continue to react for half an hour, concentrate to dryness, and redissolve the resulting oil with 5 ml of dichloromethane to obtain a dichloromethane solution of monomethyl suberate chloride. Take 0.5 g of compound I-88, dissolve it in 5 ml of dichloromethane, add 0.2 g of triethylamine, cool it to 5 degrees Celsius in an ice-water bath, and slowly drop the dichloromethane solution of monomethyl suberate chloride obtained in the previous step into the reaction system. After the addition is completed, remove the ice-water bath and warm it to room temperature, and then heat it to reflux at 40 degrees Celsius for 16 hours until the raw material point disappears completely. Add 40 ml of dichloromethane and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of dichloromethane, combine the organic layers, wash twice with 10 ml of 0.1M hydrochloric acid, wash once with water, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, and concentrate to dryness. Dissolve the obtained compound with 10 ml of methanol, take 0.1 g of lithium hydroxide and dissolve it in 2 ml of water, add it to the reaction system, and react for 6 hours until the raw material point disappears. Concentrate and evaporate the methanol, extract the water layer with 10 ml of ethyl acetate once, adjust the pH value to 6 with 1M hydrochloric acid, extract three times with 30 ml of ethyl acetate, combine the organic layers, backwash once with water, dry with 5 g of anhydrous sodium sulfate, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The obtained crude product is purified by silica gel column chromatography to obtain compound I-187.

[1173] 1HNMR (CDCl3, 400MHz): δ6.79-6.72(m,2H),5.90-5.80(m,1H),5.17-5.05(m,1H),5.03-4.97(m,1H),3.06-2.94(m,1H),2.49–2.19(m,6H),2 .16–1.78(m,5H),1.70-1.56(m,10H),1.55–1.41(m,1H),1.40-1.34(m ,7H),1.34–1.08(m,8H),1.08–0.94(m,7H),1.05(s,3H),0.74(s,3H).

[1174] ESI-MS m / z:688.15[M-1] -

[1175] Example 188 Synthesis of Compound I-188

[1176]

[1177] Using compound I-91 as raw material, the synthesis method is similar to Example 187 to obtain compound I-188.

[1178] ESI-MS m / z:732.10[M-1] -

[1179] Example 189 Synthesis of Compound I-189

[1180]

[1181] Using compound I-97 as raw material, the synthesis method is similar to Example 187 to obtain compound I-189.

[1182] ESI-MS m / z:702.17[M-1] -

[1183] Example 190 Synthesis of Compound I-190

[1184]

[1185] Using compound I-100 as raw material, the synthesis method is similar to Example 187 to obtain compound I-190.

[1186] ESI-MS m / z:746.12[M-1] -

[1187] Example 191 Synthesis of Compound I-191

[1188]

[1189] Dissolve 0.5 g of compound I-88 in 10 ml of anhydrous pyridine, cool to 5 degrees Celsius in an ice-water bath, add phosphorus oxychloride dropwise with stirring, stir for 2 hours, add ice water dropwise and stir overnight, extract with ethyl acetate and concentrate to precipitate a light yellow solid, which is purified by silica gel column chromatography to obtain compound I-191.

[1190] ESI-MS m / z:635.03[M+Na] +

[1191] Compound I-191 was dissolved in 2 equivalents of 1N sodium hydroxide solution, stirred for 30 minutes, and treated with acetone to precipitate an off-white solid to obtain the sodium salt I-191-1 of compound I-191, with the following structure:

[1192]

[1193] Example 192 Synthesis of Compound I-192

[1194]

[1195] Using compound I-91 as raw material, the synthesis method is similar to Example 191 to obtain compound I-192.

[1196] ESI-MS m / z:679.18[M+Na] +

[1197] Using a method similar to Example 191, the sodium salt of compound I-192 I-192-1 was obtained, and the structure is as follows:

[1198]

[1199] Example 193 Synthesis of Compound I-193

[1200]

[1201] Using compound I-97 as raw material, the synthesis method is similar to Example 191 to obtain compound I-193.

[1202] ESI-MS m / z:649.05[M+Na] +

[1203] Using a method similar to Example 191, the sodium salt of compound I-193 I-193-1 was obtained, and the structure is as follows:

[1204]

[1205] Example 194 Synthesis of Compound I-194

[1206]

[1207] Using compound I-100 as raw material, the synthesis method is similar to Example 191 to obtain compound I-194.

[1208] ESI-MS m / z:692.99[M+Na] +

[1209] Using a method similar to Example 191, the sodium salt of compound I-194 I-194-1 was obtained, and the structure is as follows:

[1210]

[1211] Example 195 Synthesis of Compound I-195

[1212]

[1213] Dissolve 0.5 g of compound I-88 in 5 ml of DMF, add 0.15 g of BOC-glycine, cool to 0 degrees Celsius in an ice bath, slowly add 0.3 g of DCC, and continue to react for 4 hours after all the addition until all the raw material points disappear. Add 60 ml of ethyl acetate and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of ethyl acetate, combine the organic layers, wash once with water, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The concentrate obtained is deprotected from BOC with hydrochloric acid gas to obtain compound I-195.

[1214] ESI-MS m / z:625.07[M-1] -

[1215] Example 196 Synthesis of Compound I-196

[1216]

[1217] Using compound I-91 as raw material, the synthesis method is similar to Example 195 to obtain compound I-196.

[1218] ESI-MS m / z:669.00[M-1] -

[1219] Example 197 Synthesis of Compound I-197

[1220]

[1221] Using compound I-97 as raw material, the synthesis method is similar to Example 195 to obtain compound I-197.

[1222] ESI-MS m / z:603.11[M-1] -

[1223] Example 198 Synthesis of Compound I-198

[1224]

[1225] Using compound I-100 as raw material, the synthesis method is similar to Example 195 to obtain compound I-198.

[1226] ESI-MS m / z:647.06[M-1] -

[1227] Example 199 Synthesis of Compound I-199

[1228]

[1229] Take 0.5 g of compound I-37, dissolve it in 10 ml of tetrahydrofuran, add 0.2 g of DMF, cool it to 0 degrees Celsius in an ice bath, slowly add phosphorus oxychloride dropwise, and continue to react for 4 hours after the addition is completed until the raw material reacts completely. Add 60 ml of ethyl acetate and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of ethyl acetate, combine the organic layers, wash them with water once, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The crude product is purified by silica gel column chromatography to obtain compound I-199.

[1230] ESI-MS m / z:524.09[M-1] -

[1231] Example 200 Synthesis of Compound I-200

[1232]

[1233] Using compound I-66 as raw material, the synthesis method is similar to Example 199 to obtain compound I-200.

[1234] ESI-MS m / z:538.11[M-1] -

[1235] Example 201 Synthesis of Compound I-201

[1236]

[1237] Take 0.5 g of compound I-37, dissolve it in 10 ml of dichloromethane, add 0.3 g of aluminum chloride, cool it to 0 degrees Celsius in an ice bath, slowly add a dichloromethane solution of acetyl chloride dropwise, and continue to react for 4 hours after the addition is completed, until the raw material disappears completely. Add 40 ml of dichloromethane and 30 ml of water to the system, stir well and let stand for stratification, extract the water layer twice with 15 ml of dichloromethane, combine the organic layers, wash them with water once, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The crude product obtained is purified by silica gel column chromatography to obtain compound I-201.

[1238] 1 HNMR (CDCl3, 400MHz): δ7.56(d,J=3.9Hz,1H),7.04-6.96(m,1H),5.89(s,1H),5.28-5.17(m,1H),2.90(dd,J=12.8,5.6Hz,1H),2.53(s,3H),2.57 –2.39(m,3H),2.30–2.14(m,5H),2.15-1.76(m,7H),1.72–1.44(m,4H),1 .32(s,3H),1.30–1.09(m,4H),1.09–0.90(m,8H),0.74(d,J=3.8Hz,3H).

[1239] ESI-MS m / z:538.11[M-1] -

[1240] Example 202 Synthesis of Compound I-202

[1241]

[1242] Using compound I-66 as raw material, the synthesis method is similar to Example 201 to obtain compound I-202.

[1243] ESI-MS m / z:552.22[M-1] -

[1244] Example 203 Synthesis of Compound I-203

[1245]

[1246] Take 0.5 g of compound I-72, dissolve it in 10 ml of ethanol, add 40% dimethylamine aqueous solution, heat and reflux overnight until the raw material reacts completely. Add 60 ml of ethyl acetate to the system, stir well and let stand to separate the layers, extract the water layer twice with 15 ml of ethyl acetate, combine the organic layers, wash them with water once, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The crude product is purified by silica gel column chromatography to obtain compound I-203.

[1247] ESI-MS m / z:539.14[M-1] -

[1248] Example 204 Synthesis of Compound I-204

[1249]

[1250] Using compound I-80 as raw material, the synthesis method is similar to Example 203 to obtain compound I-204.

[1251] ESI-MS m / z:553.15[M-1] -

[1252] Example 205 Synthesis of Compound I-205

[1253]

[1254] Take 0.5 g of compound I-37, dissolve it in 10 ml of acetonitrile, add 0.2 g of suberic acid, 0.5 g of trifluoroacetic anhydride, 0.15 g of 80% phosphoric acid aqueous solution, and heat at 50 degrees Celsius for 3-4 hours until the raw material disappears completely. Add 60 ml of ethyl acetate and 30 ml of water to the system, stir well and let stand to separate, extract the water layer twice with 15 ml of ethyl acetate, combine the organic layers, wash with water once, dry the organic layer with 5 g of anhydrous sodium sulfate for 20 minutes, filter to remove sodium sulfate, and concentrate the filtrate to dryness. The crude product is purified by silica gel column chromatography to obtain compound I-205.

[1255] ESI-MS m / z:562.18[M-1] -

[1256] Example 206 Synthesis of Compound I-206

[1257]

[1258] Using compound I-66 as raw material, the synthesis method is similar to Example 205 to obtain compound I-206.

[1259] ESI-MS m / z:666.19[M-1] -

[1260] Example 207 Preparation of Pharmaceutical Tablet Compositions of Compounds of the Invention

[1261] The pharmaceutical tablet composition of compound I-70 comprises 1 part by weight of compound I-70, 0.1-0.3 parts by weight of lactose, 0.4-0.2 parts by weight of starch, 0.008-0.014 parts by weight of sodium carboxymethyl starch, an appropriate amount of povidone K30, 0.01-0.05 parts by weight of magnesium stearate, and 0.5 parts by weight of 40% ethanol; tablets are prepared according to the above proportions to obtain pharmaceutical tablets of compound I-70 of the present invention, each tablet containing 50-1500 mg of compound 1-70.

[1262] Using the same method as above, pharmaceutical tablet compositions of compounds I-72, I-74, I-77, I-80, I-88, I-91, I-97, I-100, I-106, I-109, I-112, and I-115 were prepared respectively.

[1263] Example 208 Preparation of the pharmaceutical capsule composition of the compound of the present invention

[1264] The pharmaceutical capsule composition of compound I-115 contains 300 grams of compound I-115, 193 grams of microcrystalline cellulose, 7 grams of micro-powder silica gel, a total of 500 grams and No. 2 hollow capsules; or contains 1200 grams of compound I-115, 279 grams of microcrystalline cellulose, 21 grams of micro-powder silica gel, a total of 1500 grams and No. 00 hollow capsules.

[1265] The preparation method is:

[1266] a. Mixing compound I-115, microcrystalline cellulose and micropowdered silica gel to obtain a mixed powder;

[1267] b. Pass the mixed powder through a 120-mesh sieve, fill it into capsules and seal them. Make a total of 1,000 capsules.

[1268] Each capsule contains 300 mg or 1200 mg of compound I-115.

[1269] Using the same method as above, pharmaceutical capsule compositions of compounds 1-70, I-72, I-74, I-77, I-80, I-88, I-91, I-97, I-100, I-106, I-109, and I-112 were prepared respectively.

[1270] The following experimental examples demonstrate the beneficial effects of the compounds of the present invention.

[1271] Experimental Example 1 Experiment on the inhibition of Clostridium difficile spore germination by the compounds of the present invention

[1272] (1) Experimental methods

[1273] According to the method disclosed in The Journal of Infectious Diseases 2013; 207: 1498-504, spores of ATCC BBA1870, ATCC 43255 and ATCC 630 strains were cultured and purified and stored at 4 degrees Celsius.

[1274] Spore preparation: Heat activate C. difficile spores stored at 4°C at 65°C for 30 minutes, centrifuge at 9400g for 2 minutes, and then wash three times to remove any spontaneously germinated spores. Resuspend in BHIS medium, use a microplate reader to measure the absorbance at 580nm, and adjust the spore density so that the OD value of 100μl spores in a 96-well microplate is around 1.0.

[1275] Control drugs: Three bile acid derivative compounds CamSA, compound 20β (prepared by the method of Journal of Medicinal Chemistry 2017, 60(8): 3451-3471), and compound 12a (prepared by the method of Journal of Medicinal Chemistry 2018, 61, 6759-6778) were used as control drugs.

[1276] Compound preparation: Dissolve the compound of the present invention and positive drugs CamSA, 20β, 12a in DMSO to prepare a 10mM stock solution for immediate use. Dilute the compound appropriately when used so that the compound detection concentration range is 0.125-256μM, with a total of 11 two-fold dilution concentration gradients.

[1277] The experiment was tested in a 96-well cell culture plate. The temperature was kept constant at 37 degrees Celsius during the test. The final volume of each well of the 96-well plate was 200 μl. The buffer used BHIS medium. 150 μl of spores and drugs were added to the wells in advance, and then 50 μl of 4 mg / ml sodium taurocholate was added. The OD580 was immediately tested every 1 min using an ELISA reader for 60 min. A germination agent control group and a non-germination group were set up. After the test, the final OD value of each well was compared with the initial value and compared with the germination agent group to calculate the germination rate and inhibition rate. The germination rate calculation formula is:

[1278]

[1279] The inhibition rate calculation formula is:

[1280] Inhibition rate = 100% - germination rate.

[1281] The minimum concentration that completely inhibits spore germination is the compound MIC value, and the results are recorded in Table 1 below.

[1282] (2) Experimental results

[1283] Table 1 Results of inhibition of Clostridium difficile spore germination by the compounds of the present invention

[1284]

[1285]

[1286]

[1287] As can be seen from Table 1, the compounds of the present invention can effectively inhibit the germination of Clostridium difficile spores, among which most of the compounds have a better inhibitory effect on the germination of Clostridium difficile spores than the control compound CamSA. In particular, many compounds such as I-32, I-35, I-37, I-41, I-48, I-50, and I-51 have MIC values ​​of various Clostridium difficile spore germination as low as 1 μM or less, showing particularly significant inhibitory activity on spore germination.

[1288] In summary, the present invention provides a compound represented by formula (I), which can effectively inhibit the germination of Clostridium difficile spores, has significant antibacterial activity, and has very good application prospects in the preparation of drugs for preventing and / or treating Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases, or complications of Clostridium difficile infectious diseases.

Claims

1. A compound represented by the following formula (I), or a salt thereof: in, R 1 , R 2 , R 4 , R 7 independently selected from H; R 3 Selected from =O or -OCH 3 ; R 5 , R 8 Selected from H, -OH; R 6 Selected from -OH, -NH 2 、-OSO 3 H or its salt, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, amino acid ester group or its salt, -OCO(CH 2 ) m CH 3 , =0, the amino acid ester group is the group remaining after removing a hydrogen atom from the carboxyl group on the amino acid, wherein m=an integer of 0-9; R 3 , R 6 At least one of them is selected from =O, or when R 3 Selected from -OCH 3 When R 6 Selected from -OSO 3 H, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, -OCO(CH 2 ) m CH 3 ; Or, R 1 With R 2 Connect to form a double bond; R 9 Selected from H, or R 9 With R 4 or R 5 Connect to form a double bond; R 10 Selected from H, C 1-13 Straight or branched alkyl, -(CH 2 ) n COOH, -(CH 2 ) n+1 NH 2 、-(CH 2 ) n -B; wherein n=an integer from 0 to 4; B is a benzene ring or a cycloalkyl group; wherein the cycloalkyl group is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group; A is selected from benzene ring, thiophene, furan, pyridine, thiazole; It is a single bond or a double bond.

2. A compound represented by the following formula (IIA), or a salt thereof: in, R 1 , R 2 , R 4 , R 7 independently selected from H; R 3 Selected from =O; R 5 , R 8 Selected from H, -OH; R 6 Selected from -OH, -NH 2 、-OSO 3 H or its salt, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, amino acid ester group or its salt, -OCO(CH 2 ) m CH 3 , =0, the amino acid ester group is the group remaining after removing a hydrogen atom from the carboxyl group on the amino acid, wherein m=an integer of 0-9; R 3 , R 6 At least one of them is selected from =O, or when R 3 Selected from -OCH 3 When R 6 Selected from -OSO 3 H, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, -OCO(CH 2 ) m CH 3 ; Or, R 1 With R 2 Connect to form a double bond; R 9 Selected from H, or R 9 With R 4 or R 5 Connect to form a double bond; R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH 2 ) n COOH, -(CH 2 ) n+1 NH 2 、-(CH 2 ) n -B; wherein n=an integer from 0 to 4; B is a benzene ring or a cycloalkyl group; wherein the cycloalkyl group is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group; R 11 Selected from H, C 1-3 Straight or branched alkyl, -CHO, sulfonic acid, F, Cl, Br, I, -(CH 2 ) n2 COOH, -N[(CH 2 ) n2 CH 3 ] 2 、-COCH 3 、-CO(CH 2 ) n3 COOH; where n 2 = integer from 0 to 3, n 3 = an integer from 1 to 6; R 12 H; R 13 H or C 1-3 A straight chain or branched chain alkyl group.

3. The compound according to claim 2, or a salt thereof, Features: The compound of formula (IIA) has a structure as shown in the following formula (IIIA-1) or (IIIA-2): Among them, R 5 , R 8 Selected from H, -OH; R 6 Selected from -OH, -NH 2 、-OSO 3 H or its salt, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, amino acid ester group or its salt, -OCO(CH 2 ) m CH 3 , the amino acid ester group is the group remaining after removing a hydrogen atom from the carboxyl group on the amino acid, wherein m=an integer of 0-9; R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH 2 ) n COOH, -(CH 2 ) n+1 NH 2 、-(CH 2 ) n -B; wherein n=an integer from 0 to 4; B is a benzene ring or a cycloalkyl group; wherein the cycloalkyl group is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group; R 11 Selected from H, C 1-3 Straight or branched alkyl, -CHO, sulfonic acid, F, Cl, Br, I, -(CH 2 ) n2 COOH, -N[(CH 2 ) n2 CH 3 ] 2 、-COCH 3 、-CO(CH 2 ) n3 COOH; where n 2 = integer from 0 to 3, n 3 = an integer from 1 to 6; R 12 H; R 13 H or C 1-3 A straight chain or branched chain alkyl group.

4. The compound according to claim 3, or a salt thereof, Features: The compound of formula (IIIA-1) has the structure described by the following formula (IVA-1): Among them, R 6 Selected from -OH, -NH 2 、-OSO 3 H or its salt, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, amino acid ester group or its salt, -OCO(CH 2 ) m CH 3 , the amino acid ester group is the group remaining after removing a hydrogen atom from the carboxyl group on the amino acid, wherein m=an integer of 0-9; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 independently selected from H, -CHO, sulfonic acid, F, Cl, Br, I, -N[(CH 2 ) n2 CH 3 ] 2 、-COCH 3 、-CO(CH 2 ) n3 COOH; where n 2 = integer from 0 to 3, n 3 = an integer from 1 to 6; R 12 , R 13 Independently selected from H.

5. The compound according to claim 3, or a salt thereof, Features: The compound of formula (IIIA-1) has the structure described by the following formula (VA-1): Among them, R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH 2 ) n COOH, -(CH 2 ) n -B; wherein n=an integer from 0 to 4; B is selected from a benzene ring and a cycloalkyl group; wherein the cycloalkyl group is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group; R 11 Selected from H, C 1-3 Straight or branched alkyl, sulfonic acid, F, Cl, Br, I, -(CH 2 ) n2 COOH, wherein n2=an integer from 0 to 3; R 12 H; R 13 H or C 1-3 A straight chain or branched chain alkyl group.

6. A compound having a structure represented by the following formula (VIA-1), or a salt thereof: in, R 5 Selected from -OH; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I; R 12 , R 13 Independently selected from H.

7. The compound according to claim 3, or a salt thereof, Features: The compound of formula (IIIA-1) has a structure as shown in the following formula (VIIIA-1): Among them, R 5 , R 6 Selected from -OH; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I; R 12 , R 13 Independently selected from H.

8. The compound according to claim 4, or a salt thereof, Features: The compound of formula (IVA-1) has a structure as described in formula (XIA-1) or (XIA-2): Among them, R 6 Selected from -OH, -NH 2 、-OSO 3 H or its salt, -OPO(OH) 2 or its salts, -OCO(CH 2 ) m COOH or its salt, amino acid ester group or its salt, -OCO(CH 2 ) m CH 3 , the amino acid ester group is the group remaining after removing a hydrogen atom from the carboxyl group on the amino acid, wherein m=an integer of 0-9; R 10 Selected from H, C 1-4 The alkyl group; R 11 Selected from H, -CHO, sulfonic acid, F, Cl, Br, I, -N[(CH 2 ) n2 CH 3 ] 2 、-COCH 3 、-CO(CH 2 ) n3 COOH; wherein n2=an integer from 0 to 3, n3=an integer from 1 to 6; R 12 , R 13 Independently selected from H.

9. A compound having a structure represented by the following formula (XII-1) or (XII-2), or a salt thereof: in, R 10 Selected from H, C 1-4 The alkyl group; R 11 Selected from H, C 1-3 Straight or branched alkyl, sulfonic acid, F, Cl, Br, I, -(CH 2 ) n2 COOH, wherein n2=an integer from 0 to 3.

10. The compound according to claim 9, or a salt thereof, Features: The C 1-4 The alkyl group is cyclopropyl.

11. The compound according to claim 2, or a salt thereof, Features: The compound of formula (IIA) has a structure as shown in the following formula (IIIB): Among them, R 5 , R 8 independently selected from H; R 6 Selected from =O, -OH, -OCO(CH 2 ) m CH 3 ; wherein m = an integer from 0 to 9; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I; R 12 , R 13 Independently selected from H.

12. The compound according to claim 2, or a salt thereof, Features The compound of formula (IIA) has a structure as shown in the following formula (IIIC): Among them, R 5 , R 8 Selected from H; R 6 Selected from =O, -OH, -OCO(CH 2 ) m CH3; wherein m = an integer from 0 to 9; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 is selected from H, F, Cl, Br, I; R 12 , R 13 Independently selected from H.

13. The compound according to claim 11, or a salt thereof, Features: The compound of formula (IIIB) has a structure as shown in the following formula (IVB-3): Among them, R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I.

14. The compound according to claim 11, or a salt thereof, Features: The compound of formula (IIIB) has a structure as shown in the following formula (VB-1): Among them, R 6 Selected from -OH-OCO(CH 2 ) m CH3; wherein m = an integer from 0 to 9; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I.

15. The compound according to claim 12, or a salt thereof, Features: The compound of formula (IIIC) has the structure shown below (IVC-3): Among them, R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I.

16. The compound according to claim 12, or a salt thereof, Features: The compound of formula (IIIC) has a structure as shown in the following formula (VC-1): Among them, R 6 Selected from -OH, -OCO(CH 2 ) m CH3; wherein m = an integer from 0 to 9; R 10 Selected from H, C 1-4 A straight chain or branched alkyl group; R 11 Selected from H, F, Cl, Br, I.

17. A compound having a structure represented by the following formula (IIID), or a salt thereof: in, R 6 Selected from =O; R 10 Selected from H, C 1-4 Straight or branched alkyl, -(CH 2 ) n COOH, -(CH 2 ) n -B; wherein n=an integer from 0 to 4; B is selected from a benzene ring; R 14 Selected from H.

18. The following compound, or a salt thereof:

19. Use of the compound according to any one of claims 1 to 18, or a salt thereof, in the preparation of an antibacterial agent for inhibiting Clostridium difficile.

20. The use according to claim 19, Features: The antibacterial agent is a drug that inhibits the germination of Clostridium difficile spores.

21. The use according to claim 20, Features: The bacteriostatic agent can prevent and / or treat Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases or complications of Clostridium difficile infectious diseases.

22. The use according to claim 21, Features: The Clostridium difficile infectious disease, recurrence of Clostridium difficile infectious disease, or complication of Clostridium difficile infectious disease is caused by infection with Clostridium difficile spores; The Clostridium difficile infectious disease complication is a digestive tract infection syndrome caused by Clostridium difficile spore infection.

23. The use according to claim 22, Features: The digestive tract infection syndrome is selected from pseudomembranous colitis, diverticulitis, and antibiotic-associated diarrhea.

24. A drug for inhibiting Clostridium difficile spores, Features: The drug is a preparation prepared by using the compound according to any one of claims 1 to 18 or its salt as an active ingredient and adding pharmaceutically acceptable excipients.

25. The drug according to claim 24, Features: The pharmaceutically acceptable excipient is selected from any one or more of a diluent, a filler, a colorant, a glidant, a lubricant, a binder, a stabilizer, a suspending agent or a buffer.

26. The medicament according to claim 24 or 25, Features: The preparation is an oral preparation.

27. The medicament according to claim 26, Features: The oral preparation is selected from granules, capsules, tablets and pills.

28. The medicament according to any one of claims 24 to 27, Features: The dosage of the active ingredient contained in the pharmaceutical unit preparation is 5-2500 mg.